

MODIFIED CELLS AND METHODS OF USING SAME**BACKGROUND OF THE INVENTION****5 FIELD OF THE INVENTION**

The present invention relates generally to a model system to identify haematopoietic cells of particular lineages and their stage of differentiation. More particularly, the present invention provides genetically modified cells and non-human animals comprising such
10 cells which carry a genetic marker of terminal differentiation modified to co-produce a reporter molecule capable of eliciting an identifiable signal and their use in identifying molecules capable of modulating the differentiation or transformation status of cells, such as, without limitation, embryonic cells during development, cells with aberrant differentiation such as cancer cells, and cells of the haematopoietic cell lineages such as,
15 for example, B and/or T cells. Identified molecules form the basis for pharmaceutical compositions for therapeutic and prophylactic application.

DESCRIPTION OF THE PRIOR ART

20 Bibliographic details of references in the subject specification are also listed at the end of the specification.

Reference to any prior art in this specification is not, and should not be taken as, an acknowledgement or any form of suggestion that this prior art forms part of the common
25 general knowledge in any country.

Cellular life involves a myriad of alternative and highly regulated biochemical pathways directing changes in cell division, differentiation, morphogenesis and apoptosis. Cells vary in their potential to divide and/or differentiate. For example, the embryo comprises
30 totipotent cells retaining the ability to differentiate into any cell type. Other cell types including stem cells are pluripotent and may ultimately differentiate into a range of but not

all cell phenotypes. Some cells become committed to one final form: they are terminally differentiated.

Changes which block normal maturation of cells into terminally differentiated cells or
5 which prevent apoptosis can act as triggers for tumor development characterized by
uncontrolled cell division without differentiation or cell death. Thus, agents which
promote differentiation and normal apoptosis may switch off tumor development.

Molecules which are expressed during the time of terminal differentiation of particular cell
10 types have been intensely studied. However, in order to understand the sequence of events
during this period at a molecular level it is necessary to understand the temporal and spatial
expression patterns of molecules which are expressed in this phase of development.

B-lymphocyte-induced maturation factor (Blimp) is a 98kDa transcription factor which
15 was originally identified as being induced during the differentiation of a B-cell lymphoma
cell line (Turner *et al.*, *Cell* 77:297, 1994). The corresponding factor from human cells is
referred to as PRDM-1. It has been proposed that Blimp-1 has a pre-eminent role in
regulating B-cell terminal differentiation. Specifically, *Blimp-1* is expressed in antibody
secreting cells (ASC) from man and mouse but it is not expressed in memory cells
20 (Angelin-Duclos *et al.*, *J Immunol* 165:5462, 2000). Ectopic expression of *Blimp-1* is
sufficient to drive terminal differentiation of lymphomas and primary B-cells into ASC
cells (Turner *et al.*, (*supra*), Schliephake *et al.*, *Eur J Immunol* 26:268, 1996; Messika *et al.*,
J Exp Med 188:515, 1998; Knodel *et al.*, *Eur J Immunol* 31:1972, 2001). Blocking
expression of *Blimp-1* through antisense or dominant-interfering approaches suppresses
25 cell-cycle exit which is thought to be essential for full ASC differentiation (Soro *et al.*, *J*
Immunol 163:611, 1999; Angelin-Duclos *et al.*, *J Immunol* 165:5462, 2000; Johnson *et al.*,
Eur J Immunol 32:3765, 2002). Also, mice which lack Blimp-1 in B-cells produce very
little immunoglobulin and have a markedly reduced ASC compartment. (Shapiro-Shelef *et al.*,
Immunity 19:607, 2003.).

30

It was initially reported that Blimp-1 is only produced in cells of the B-cell lineage,

however, it is now evident that Blimp-1 is also produced during myeloid differentiation (Keller *et al.*, *Genes Dev* 5:868, 1991, Chang *et al.*, *Nat Immunol* 1:169, 2000). Blimp-1 is required for the repression of *c-myc* which is involved in myeloid differentiation (Chang *et al.*, (*supra*), 2000; Marcu *et al.*, *Annu Rev Biochem* 61:809, 1992). Over production of
5 Blimp-1 in U937 cells for example is sufficient to induce macrophage differentiation (Chang *et al.*, (*supra*), 2000). Thus, repression of *c-myc* by Blimp-1 in macrophages and B-cells is a feature of terminal differentiation in these two lineages. Blimp-1 is also broadly produced during mouse and *Xenopus* embryonic development (de Souza *et al.*, *Embo J* 18:6062, 1999; Rosenbaum *et al.*, *Embo J*, 9:897, 1990).

10

B-lymphocytes are among the most intensively studied eukaryotic cell types but while the early steps of B-cell development are relatively well characterized, much less is known about the processes which control the final differentiation of B-lymphocytes into ASC. ASC (plasma cells) are the direct mediators of the humoral immune response. They
15 secrete a large amount of serum immunoglobulin essential for protective immunity. The terminal differentiation of B-lymphocytes into ASC is, therefore, a subject of intense therapeutic interest. For example, terminal differentiation to ASC is a crucial element in effective vaccination strategies. Furthermore, multiple myeloma results from the failure of an ASC to complete the differentiation pathway.

20

However, ASC represent a very rare population of highly specialised cells located mostly in the bone marrow and spleen. ASC populations in mice and man comprise cells of heterogeneous life span and cell surface phenotype making a definitive prospective isolation of pure ASC impossible (Fong *et al.*, *Proc Natl Acad Sci U S A* 11:11, 2003;
25 Medina *et al.*, *Blood* 99:2154, 2002; O'Connor *et al.*, *J. Exp Med* 195:737, 2002; Manz *et al.*, *Curr Opin Immunol* 14:517, 2002; Underhill *et al.*, *Blood* 24:24, 2003).

T-cell terminal differentiation programs are poorly understood (Sprent *et al.*, *Immunol Lett* 85:145-149, 2003). In response to infection, antigen-specific T cells differentiate into
30 effector cells and undergo massive clonal expansion. Homeostasis of T cell numbers is maintained by the subsequent contraction phase where >90% of effector cells are

eliminated with a small fraction becoming memory T cells (Sprent *et al.*, *Annu Rev Immunol* 20:551-579, 2002). This process has been proposed to be under genetic control as the contraction is independent of the dose or duration of infection (Badovinac *et al.*, *Nat Immunol* 5:809-817, 2004; Badovinac *et al.*, *Nat Immunol* 3:619-626, 2002). The ability to
5 control T cell numbers is essential as enhanced expansion due to the lack of T-regulatory cells (Khattari *et al.*, *Nat Immunol* 4:337-342, 2003; Hori *et al.*, *Science* 299:1057-1061, 2003; Fontenot *et al.*, *Nat Immunol* 4:330-336, 2003), the loss of the down-regulatory molecule CTLA-4 (Chambers *et al.*, *Immunity* 7:885-895, 1997) or genetic deficiencies in non-obese diabetic (NOD) mice result in autoimmunity.

10

The ability to monitor terminal differentiation of ASC, T-cells and other cells of the haematopoietic system in a wide range of contexts and under various stimuli would be extremely valuable in developing strategies and reagents for use in the treatment and/or prophylaxis of a range of conditions associated with aberrant differentiation, such cancer
15 autoimmune disease, or with harnessing normal developmental programs such as in the development of an appropriate immune response.

SUMMARY OF THE INVENTION

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the
5 inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.

Nucleotide and amino acid sequences are referred to by a sequence identifier number (SEQ ID NO:). The SEQ ID NOs: correspond numerically to the sequence identifiers <400>1
10 (SEQ ID NO:1), <400>2 (SEQ ID NO:2), etc. A summary of sequence identifiers is provided in Table 1. A sequence listing is provided after the claims.

Genes and other genetic material (eg mRNA, constructs etc) are represented in italics and their proteinaceous expression products are represented in non-italicised form. Thus, the
15 transcription factor Blimp is the expression product of *Blimp*. The term "Blimp" or "*Blimp*" is used to denote all homologs or variant molecules derived from any animal or mammalian species, including a human homolog. Accordingly, human *PRDM-1* and its product, PRDM-1 are encompassed in the terms *Blimp* or Blimp. Unless otherwise stated, reference to Blimp is a reference to a functional form of the polypeptide and reference to a
20 modified *Blimp* is a reference to the gene or allele sequences encoding a functional form of Blimp.

The present invention is predicated, in part, on the identification of the role of Blimp in the differentiation of haematopoietic and embryonic cells. By screening for the presence of
25 Blimp, or the level of Blimp, a determination can be made as to the stage of terminal differentiation of a cell. The identification of the role of Blimp further enables substantially homogeneous populations of particular haematopoietic cells to be identified such as, but not limited to, ASC (plasma cells).

30 More particularly, the present invention provides a genetically modified cell or an *in vivo* or *in vitro* system comprising cells which co-express genetic material which encodes

Blimp and a reporter molecule. Detection of reporter activity in cells of a haematopoietic lineage, such as but not limited to a lymphocyte lineage, is indicative that cells having reporter activity and producing functional Blimp are committed to terminal differentiation. Thus, the detection of reporter-active B-cells producing functional Blimp is an indication
5 that these cells are committed to differentiate into an antibody secreting cells (ASC). Also, as described herein the detection of reporter activity in T cells expressing a functional *Blimp*, is indicative that these cells are activated/memory T cells, such as activated CD4⁺ T-cells or effector CD8⁺ T-cells. The present invention provides therefore, genetically modified cells or non-human animals comprising such cells which facilitate monitoring the
10 differentiation or transformation status of particular cells under various conditions or in the presence of various stimuli or agents. The present invention further provides screening methods, including high through-put screening methods, for identifying molecules capable of modulating the differentiation or transformation status of cells, such as, without limitation, embryonic cells including stem cells during development, cells with aberrant
15 differentiation such as cancer cells, and cells of the haematopoietic cell lineages such as, for example B and/or T cells.

Specifically, a genetically modified cell, or a non-human organism comprising such cells, is provided by the present invention. In one embodiment, the cells produce Blimp
20 translated from an mRNA modified to encode a reporter molecule. Preferably, the reporter molecule encoding sequence is inserted into an intron of a Blimp allele. When the modified Blimp allele is present in heterozygous form, the other allele will express a functional Blimp. In some embodiments, the modified allele may express a functional Blimp polypeptide or a functional form thereof. In other embodiment the modified allele
25 expressed a non-functional Blimp polypeptide. In one embodiment the modified cells are useful in *in vivo* or *in vitro* cellular model systems to identify and isolate, *inter alia*, ASC. In another embodiment, the modified cells are useful for monitoring the differentiation status of haematopoietic such as T-cells and/or B-cells in a wide range of assays.

30 In one aspect, the present invention provides a genetically modified cell or non-human organism comprising such cells comprising modified genetic material which when

expressed produces a polypeptide co-expressed with a reporter molecule and wherein the polypeptide is associated with terminal differentiation of a haematopoietic cell. Preferably, the genetic material is a *Blimp* gene or a part, fragment, homolog, derivative or functional form thereof. Furthermore, the identification of the reporter molecule in B-cell lineage
5 cells indicates that such cells are committed to differentiate or have differentiated into ASC. Alternatively, reporter molecule activity in cells of a T cell lineage indicates that these cells are activated. Thus, as described herein, the presence of Blimp in a lymphocyte indicates that the cell is terminally differentiated or is committed to terminal differentiation. Exemplary T-cells include CD4⁺ T-cells and CD8⁺ T-cells and exemplary
10 B-cells are ASC. Where a non-functional Blimp polypeptide is produced, detection of reporter-active cells indicates that the cells have been exposed to conditions sufficient to render them terminally differentiated if they had been able to produce a functional Blimp polypeptide.

15 Genetically modified non-human organisms may be provided in the form of gametes, embryos or ES cells for transplantation. Embryos are preferably maintained in a frozen state and may optionally be sold with instructions for use. Targeting constructs and genetically modified cells are also preferably maintained in a frozen state and may optionally be sold with instructions for use. All such cells are referred to herein as an *in*
20 *vivo* or *in vitro* cellular model system.

The present invention provides a system for monitoring gene expression and differentiation fate in cells *in vivo* and *in vitro* at the single cell, tissue and organism level. Thus, reporter activity may be monitored in live cells and gene expression monitored in fixed tissues.
25 Preferably, the reporter expression cassette encodes a fluorescent or other light emitting moiety. The availability of organisms and cells which report the expression of *Blimp-1* for example as a marker for terminal differentiation of a particular lineage or cell will be an extremely useful tool in a wide range of applications. In relation to cells of the B-cell lineage, this system finds broad application in the study, isolation and monitoring of ASC.
30 As previously mentioned, ASC have not hitherto been available for study although these cells are crucial for an effective antibody response. Furthermore, aberrant differentiation

in ASC causes multiple myeloma in man making them an important cell type to study for this reason.

In a related embodiment, the present invention provides a method for phenotyping and/or
5 monitoring a cell of the haematopoietic system comprising screening a genetically
modified cell or non-human animal comprising such cells comprising a modified *Blimp*
gene encoding a Blimp protein which when expressed co-expresses Blimp or a part,
fragment, variant, homolog or functional or non-functional form thereof and a reporter
molecule, wherein detection of reporter activity is indicative or predictive of a cellular
10 phenotype and/or commitment of a cell to terminally differentiate. Haematopoietic cells
include without limitation B-cells, T-cells, dendritic cells, macrophages, natural killer
cells, granulocytes, erythrocytes, eosinophils, megakaryocytes, bone marrow, splenic,
dermal, or stromal cells or their derivatives. In one particular embodiment, the
haematopoietic cells are lymphocytes such as B and/or T cells.

15

In a further embodiment, cells which exhibit reporter activity or changes in reporter
activity are isolated or selected from among cells which do not exhibit reporter activity.
Isolation of reporter-active cells may be by any convenient method. For example, flow
cytometry, laser scanning cytometry, chromatography and/or other equivalent procedures
20 are conveniently employed. Flow cytometric procedures are particularly preferred.
Additionally, further selection markers such as for example drug selection markers, may be
used to isolate or select the modified cells of the present invention.

The present invention also provides antagonists and agonists of *Blimp-1* expression or
25 *Blimp-1* activity. One example of an agonist of *Blimp-1* expression is a cytokine such as
but not limited to IL-21. Pharmaceutical compositions are further contemplated
comprising recombinant, synthetic or isolated forms of the present agonists and antagonists
and one or more pharmaceutically acceptable carriers, diluents or excipients. Reference to
Blimp-1 expression or production of *Blimp-1* protein includes in a single cell or within a
30 population of cells.

TABLE 1
Summary of sequence identifiers

SEQUENCE ID NO:	DESCRIPTION
1	Nucleotide sequence encoding murine Blimp-1
2	Amino acid sequence of murine Blimp-1
3	Nucleotide sequence encoding human Blimp-1 (PRDM-1)
4	Amino acid sequence of human Blimp-1 (PRDM-1)
5	Genomic nucleotide sequence of murine Blimp-1
6	Genomic nucleotide sequence of human Blimp-1 (PRDM-1)

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a diagrammatic representation of the Blimp-1 locus and a targeting strategy.

A) Structural domains of the Blimp-1 protein. The segment of the protein encoded by exons 7-8 are indicated. Acidic, N and C terminal acidic regions; PR, region of homology to the retinoblastoma interacting zinc finger protein RIZ; Pro, proline rich region; Zn, 5 Zinc fingers. B) Genomic locus of Blimp-1, indicating the 8 exons as boxes and introns as black lines. Coding regions are in grey, non-translated regions are white. Restriction enzymes used for Southern hybridisations are marked, along with the 5' and 3' probes.

Targeted allele derived from the homologous recombination event and subsequent manipulations is indicated C) Southern hybridisation on targeted and control ES cell DNA, using 5' and 3' ends of the Blimp-1 locus, to show expected products of the targeting event (4.8kb 5' arm and 4.5kb 3' arm). Expression of Blimp-1 in *blimp^{gfp/+}* LPS stimulated B cells cultured for 0-3 days *ex vivo* in IL-15 ^{+/+}IL-21. Blimp-1 expression was detected using a monoclonal antibody against mouse Blimp-1, a goat polyclonal antibody against α -actin was used as a loading control. ^{+/+}, wild type C57B1/6 mice; ^{+/T} *blimp^{gfp/+}* mice.

Figure 2 is a graphical representation showing the results of FACS analysis of Blimp^{gfp} expression in B-cells *in vivo*. A) Syndecan-1 and Blimp^{gfp} expression in lymph nodes, spleen and bone marrow in Blimp^{gfp/+} mice (upper panel) and controls (lower panel). B) Expression of Blimp^{gfp} in B220 positive B cells.

Figure 3 is a graphical and photographic representation showing the results of ELISpot analysis of Blimp^{gfp} sorted cells. Gfp positive cells were sorted from bone marrow (BM) and spleen of an untreated Blimp^{gfp/+} mouse and analysed in an ELISpot assay. Isotype specific antibodies or anti kappa antibodies were used to coat the elispot plate and to detect secreted immunoglobulins. A) Distribution of isotype specific immunoglobulins in 200 gfp-positive sorted cells (one representative experiment of three). B) Detection of kappa chain in a single representative well of an ELISpot plate (sample: sorted bone marrow cells). left, input 200 gfp-positive cells; middle, input 100 000 gfp-negative cells; right, input 100 000 unsorted cells.

Figure 4 is a graphical representation of the results of FACS analysis showing induction of antibody secreting cells with LPS *in vivo*. Blimp^{gfp/+} mice were i.v. injected with 2ug E. coli LPS. Spleens A) and bone marrows B) of these mice were analysed at indicated time points after LPS treatment. LPS induces the formation of ASC, increasing the frequency from about 0.5% to about 5% at day 3 in spleen and from about 0.05% to about 0.25% at day 4 in the bone marrow, respectively. upper panel, FACS scans for syndecan-1 and Blimp^{gfp}. middle panel, syndecan-1 and B220 in GFP-positive gated cells. lower panel, histograms for syndecan-1 and B220 expression in GFP-positive cells at indicated time points.

Figure 5A is a graphical representation of the kinetics of Blimp^{gfp} expression. Flow cytometry histograms of Blimp^{gfp} expression by stimulated B cells from Blimp^{gfp/+} mice (red line) and wild type C 57B1/6 mice (blue me) are shown. Histogram gates show a percentage of Blimp^{gfp} positive populations. Highly purified small resting B cells were stimulated recombinant CD40L, IL-4 and IL-5 (top panels) or LPS (20ug/ml) (bottom panels). Cells were harvested different days of culture time and analysed on flow cytometry. LPS stimulated cells start to express Blimp at 2 days, while in response to CD40L and IL-4/IL-5 Blimp expression become evident 3 days.

Figure 5B is a graphical representation showing that Blimp^{gfp} positive cells secrete antibodies. Blimp^{gfp/+} B cells were stimulated with LPS for four days. Cells were harvested and stained with Syndecan-1 (Synd-1) specific antibodies and GFP expressing (left panel, A-C) and non-expressing regions (left panel, D) were sorted directly to the Elispot plates coated with various isotype specific antibodies, using automated cell deposition unit. Sorted cells were processed according to the standart Elispot method. Right panels show number of Ig secreting cells in sorted regions. Most Blimp^{gfp} cells secrete Ig, while all Blimp^{gfp} negative cells do not secrete any of Ig isotypes tested.

Figure 5C is a graphical representation showing the different expression of Blimp^{gfp} in response to various stimuli. Highly purified small resting B cells were stimulated with i)

re combinant CD40L and IL-4; ii) CD40L, IL-4 and IL-5; iii) LPS; iv) LPS and IL-4; v) LPS and anti-IgD monoclonal antibody. After four days of culture cells were harvested, stained with Synd-1 specific antibody and analysed on flow cytometry. Shown here are two parameter dot plots of flow cytometry analysis.

5

Figure 6 is a graphical representation showing the results of analyses of mice transplanted with activated B-cells. Purified resting splenic B-cells of $\text{Blimp}^{\text{gfp/+}}$ mice were activated for three days in the presence of 20ug/ml LPS. 3×10^6 cells (containing about 2×10^6 gfp positive cells, i.e. antibody secreting cells, A) were washed three times with LPS and
10 transplanted into WT recipients by i.v. injection. After 7 days the recipient mice were analysed for the presence of donor ASC (B).

Figure 7A is a tabulated summary of genotyping results of mice born from $\text{Blimp}^{\text{gfp/+}}$ x $\text{blimp}^{\text{gfp/+}}$ matings. **Figure 7B** is a photographic representation of representative PCR
15 results of genotyping of mice weaned (left) or embryos at day E9.5 (right).

Figure 8 is a photographic and graphical representation of splenocytes of $\text{Blimp}^{\text{gfp/gft}}$ and $\text{Blimp}^{\text{gfp/+}}$ reconstituted mice were cultured in the presence of 20ug/ml LPS and analysed for the presence of GFP positive, i.e. antibody secreting cells, at day three (A). GFP
20 positive cells of both cultures were then sorted (B, gate R1) and analysed in an ELISpot assay. While $\text{Blimp}^{\text{gfp/+}}$ cells yielded 60-70% antibody secreting cells (B, lower panel left), $\text{Blimp}^{\text{gfp/gft}}$ gave only 5-7% antibody secreting cells which produced only tiny ELISpot's (B, lower panel, right) compared to spots produced by heterozygous cells. Detection of IgM and kappa chain in single representative wells of an ELISPOT plate (input 200 gfp-
25 positive cells).

Figure 9 is a graphical representation of the results of FACS analysis of bone marrow derived macrophages (BMM) and blood monocytes. Bone marrow cells were cultured for 7 days in the presence of 10ng/ml rMCSF, medium was changed and non-adherent cells
30 were removed at day 3 and 5 of culture. Adherent cells (BMM) were analysed for $\text{Blimp}^{\text{gfp}}$

expression (left panel). Further, MacI/Gr1 double positive blood cells were analysed in FACS (right panel) (black line - wildtype, red line - *Blimp^{gfp/+}*).

Figure 10 is a graphical representation showing FACS analysis *in vitro* generated dendritic cells (DC's). Bone marrow cells were cultured for 8 days in the presence of 100ng/ml Flt3 ligand. Cells were then cultured for another 24 hours (left column) or were stimulated with CpG (1.5uM), GM-CSF (50ng/ml), gIFN (20ng/ml) and IL-4 (20ng/ml) (middle column) or with 1ug/ml LPS (right column). *Blimp^{gfp}* expression is shown in histograms for plasmacytoid DC's and conventional DC's (solid line - wildtype, dotted line - *Blimp^{gfp/+}*).

10

Figure 11 is a graphical representation showing FACS analysis of T cells *in vivo* and *in vitro*. Thymic (left) and lymph node (middle) T cells, and *in vitro* activated CD4⁺/CD8⁺ purified lymph node cells (right) of *Blimp^{gfp/+}* mice were analysed in FACS. *Blimp^{gfp}* expression levels of gated T cell populations are shown in histograms (lower panel; black line - wildtype, red line - *Blimp^{gfp/+}*).

15

Figure 12 is a graphical representation showing *Blimp*-1 expression in the NK lineage can be detected in the *Blimp^{gfp/+}* reporter mice and induced by maturation stimuli. A) *in vivo* splenic NK cells are GFP⁺. B) Sorted NK cells from *Blimp^{gfp/+}* spleens were cultured for 4 days in IL-15, followed by 2 days in the indicated cytokine. mfi, mean fluorescence index of *Blimp^{gfp}*. C) Expression of *Blimp*-1 in ^{+/+} NK cells cultured for 7 days *ex vivo* in IL-15 ^{+/-}IL-21. *Blimp*-1 expression was detected using a monoclonal antibody against mouse *Blimp*-1, a goat polyclonal antibody against α -actin was used as a loading control.

20

Figure 13 is a representation showing the cDNA and predicted amino acid sequence of mouse *Blimp*-1/PRDM-1. The coding sequence is shown in upper case.

25

Figure 14 is a representation showing the amino acid sequence of mouse *Blimp*-1/PRDM-1 derived from the nucleotide sequence (upper case) in Figure 13.

30

Figure 15 is a representation showing the cDNA and predicted amino acid sequence of human Blimp-1/PRDM-1. The coding sequence is shown in upper case.

Figure 16 is a representation showing the amino acid sequence of human Blimp-1/PRDM-1 derived from the nucleotide sequence (upper case) in Figure 15.

Figure 17 is a representation showing the genomic nucleotide sequence of mouse *Blimp-1*. The genomic locus comprises 8 exons in bold upper case. ATG and stop codons are underlined.

10

Figure 18 is a representation showing the genomic nucleotide sequence of human *Blimp-1*. The genomic locus comprises 8 exons in upper case, bold. ATG and stop codons are underlined.

15 **Figure 19** is a graphical representation showing that Blimp-1 is expressed in activated/memory T cells. Blimp-1 deficient T cells have an activated/memory phenotype. A) Gated CD4⁺ or CD8⁺ splenic T cells of the indicated genotype were examined for GFP fluorescence and activation state. The majority of CD62L^{low} CD4⁺ T cells and CD44^{high} CD8⁺ T cells from *Blimp*^{gfp/+} mice is low for GFP, only a small number of CD4⁺ T cells (CD62L low or high) is GFP high. Blimp GFP is strongly expressed in the same population in *Blimp*^{gfp/gfp} T cells (dot blots); phenotype of Blimp-1 deficient CD4⁺ and CD8⁺ splenic T cells (histograms, solid line blimp-1^{+/+}, dotted line blimp-1gfp/gfp). B) *in vitro* culture induces Blimp-1 expression. Naïve CD4⁺ T cells were grown for two rounds in Th1/Th2 polarizing conditions. C) Western blotting for wild type Blimp-1 protein in CD4⁺ cells grown as above in Th1 or Th2 conditions. Anti-Zap-70 is used as a loading control. B cells stimulated for four days with LPS to induce plasma cell differentiation were used as a positive control. D) Mice reconstituted with the indicated genotypes were analysed post-HSV infection for the appearance of CD8⁺ T cells specific for the dominant gB₄₉₈₋₅₀₅ epitope using a gB specific tetramer. E) *in vitro* cultured gB-specific CTL show normal cytotoxic function. The HSV infection data is representative of at least three mice of each genotype.

20

25

30

Figure 20 is a representation of the molecular analysis of Blimp-1 positive CD4⁺ T cell populations. A) Blimp-1 is expressed in CD25⁺ suppressor T cells. CD25⁺ and CD25⁻ CD4⁺ T cells were sorted (left panel), and naïve CD4⁺ were differentiated under Th1 and Th2 polarizing conditions (right panel), all populations were subjected to RT-PCR analysis. B) Blimp-1 deficient CD4⁺ cells secrete high amounts of IFN γ and show defective IL-10 secretion. CD4⁺ cells were either sorted ex vivo from the spleen and restimulated with plate bound anti CD3 and CD28 for 24h or differentiated into Th1 or Th2 cells *in vitro* and subjected to re-stimulation. IL-10 and IFN γ in the supernatant was detected in an ELISA.

Figure 21 is a representation showing that Blimp-1 deficient mice develop a lethal lymphocyte hyperproliferative syndrome. A) Histological examination of *Rag1*^{-/-} mice reconstituted with control or *Blimp*^{gfp/gfp} foetal liver derived stem cells. *Blimp*^{gfp/gfp} reconstituted mice were sacrificed when moribund. The normal histological appearance of the organs from *Blimp*^{gfp/+} mice is contrasted with the lymphocyte infiltration observed in *Blimp*^{gfp/gfp} mice. B) rapid onset of morbidity in *Blimp*^{gfp/gfp} but not *Blimp*^{gfp/+} reconstituted mice. The number of animals of each genotype examined is indicated.

Figure 22 is a graphical representation of data showing that Blimp-1 regulates homeostatic proliferation of T cells. A) 3x10⁶ Naïve CD4⁺ or CD8⁺ splenic T cells from the indicated genotypes were adoptively transferred into non-irradiated *Rag2*^{-/-} recipients. Recipients were monitored for weight loss and signs of distress. Graph indicates the percentage changes in weight over the 3-4 week period. 4-6 mice were reconstituted with cells of each genotype. B) Mice that lost >10% body weight were sacrificed and splenic T cell numbers determined. C) splenomegaly of representative *Rag2*^{-/-} mice after transfer of *Blimp*^{gfp/gfp} CD8⁺ T cells. D) Flow cytometric analysis of Blimp^{gfp} expression in donor T cells 3 weeks after transfer.

Figure 23 is a representation of data showing that Blimp-1 is induced after secondary stimulation and regulates cytokine responsiveness. A) Naïve CD8⁺ T cells of the indicated

genotypes were cultured in the presence of anti-CD3/CD28 and IL-2 for 5 days before being re-seeded into secondary cultures containing IL-21 for 5 days. B) Identical cell cultures to above were stimulated with anti-CD3/CD28 with or without the indicated cytokine combinations. Total live cell number was determined at the indicated time-points
5 in primary or secondary cultures. CD44^{high} activated/memory CD8⁺ cells were subjected only to primary culture.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is predicated, in part, by the development of a method for identifying and isolating cells of the haematopoietic system or embryonic cells and/or
5 monitoring the differentiation of haematopoietic or embryonic cells, the method comprising detecting or quantifying the presence of a polypeptide (via a reporter) whose presence is associated with terminal differentiation of the cells.

In a particularly preferred embodiment, the polypeptide is Blimp or a part, fragment or
10 functional form thereof which is co-expressed with a reporter molecule.

Accordingly, one aspect of the present invention provides a genetically modified cell or non-human organism comprising such cells comprising genetic material encoding a polypeptide which when expressed produces the polypeptide co-expressed with a reporter
15 molecule and which polypeptide is associated with a cellular phenotype including a commitment in the cell to terminally differentiate.

In a further aspect, the present invention provides a genetically modified cell or non-human organism comprising such cells comprising a modified *Blimp* gene encoding a
20 Blimp polypeptide which when expressed produces Blimp or a part, fragment or functional form thereof co-expressed with a reporter molecule and wherein the presence of Blimp is associated with a cellular phenotype including a commitment in the cell to terminally differentiate.

25 In a further preferred aspect, the present invention provides a genetically modified cell or non-human organism comprising such cells comprising a modified *Blimp* gene encoding a Blimp mRNA transcript comprising a Blimp coding sequence or a part, fragment or functional form thereof and a reporter molecule encoding sequence, wherein the presence of Blimp is associated with a cellular phenotype including a commitment in the cell to
30 terminally differentiate.

Preferably, the reporter molecule encoding sequence is inserted with an intron of the *Blimp* allele. In this way, the modified *Blimp* allele co-produces the reporter from a bicistronic RNA under the control of endogenous *Blimp* regulatory elements.

5 The terms "co-expression" and "co-production" are used herein in a broad sense to refer to the transcription of two or more nucleic acid regions (expressed as one or more RNAs) at the same time or at substantially the same time and their subsequent translation (produced as one or more polypeptides) at the same or substantially the same time. Preferably, one transcript is expressed which encodes both *Blimp* or a part, fragment or functional form
10 thereof and a reporter molecule. In each case, the expression of the reporter is operatively linked to the expression of the molecule to be reported.

Reference to "cellular phenotype" herein encompasses the molecular or functional characteristics of a cell. For example, ASC cells express *Blimp-1* (a molecular marker)
15 and are functionally distinguished from other B-cells by exhibiting, *inter alia*, a high rate of Ig secretion, the absence of MHC class II molecules and low levels of surface Ig. As used herein, the term is a reference to the full range of molecular or functional characteristics, or any particular molecules or functional characteristic in addition to the molecular characteristic of modulated levels of *Blimp-1* expression.

20

The genetically modified cell or non-human organism comprising such cells may comprise cells or genetic material from any organism such as, but not limited to, humans, non-human primates, livestock, companion or laboratory test organism, reptilian or amphibian species. Preferably the genetically modified organism is a mouse or other laboratory test
25 animal such as a rat, guinea pig, pig, rabbit or sheep.

As used herein the singular forms "a", "an" and "the" include plural aspects unless the context clearly dictates otherwise. Thus, for example, reference to a "cell" includes a single cell, as well as two or more cells; reference to "a gene" includes a gene, as well as two or
30 more gene; and so forth.

The modified gene of the present invention is a marker for terminal differentiation in cells of the haematopoietic system, such as B-cell lineage cells.

Reference to a "genetically modified cell" is a reference to any cell which has been engineered to comprise a sequence of nucleotides from a coding or non-coding region of the genome which is altered relative to its pre-modified form, and its progeny. In particular, the cell is genetically modified to co-express a genetic marker of terminal differentiation and a reporter molecule encoding sequence. Preferably, the cell is genetically modified to co-express Blimp or a part, fragment or functional part thereof and a reporter molecule. The reporter molecule may be any molecule capable of directly or indirectly providing an identifiable signal. A fluorescent or other light emitting reporter molecule is particularly preferred.

Conveniently, targeting constructs are initially used to generate the modified genetic sequences in the cell or organism. Targeting constructs generally but not exclusively modify a target sequence by homologous recombination. Alternatively, a modified genetic sequence may be introduced using artificial chromosomes. Targeting or other constructs are produced and introduced into target cells using methods well known in the art which are described in molecular biology laboratory manuals such as, for example, in Sambrook, *Molecular Cloning: A Laboratory Manual*, 3rd Edition, CSHLP, CSH, NY, 2001; Ausubel (Ed) *Current Protocols in Molecular Biology*, 5th Edition, John Wiley & Sons, Inc, NY, 2002. Targeting constructs may be introduced into cells by any method such as electroporation, viral mediated transfer or microinjection. Selection markers are generally employed to initially identify cells which have successfully incorporated the targeting construct. As the skilled artisan will appreciate, the subject modified organisms may be genetically modified to express the *Blimp* allele and reporter molecule in only certain cells.

In one particular embodiment the present invention provides a nucleic acid construct suitable for use as a targeting construct said construct comprising all or a portion of an allele of *Blimp-1* and a reporter construct. The construct comprise genetic material which encodes a functionally active Blimp-1 polypeptide or a functionally inactive Blimp-1

polypeptide. In a particular embodiment, the construct encodes a partial Blimp-1 polypeptide which lacks a zinc finger domain comprising a DNA binding motif. In a particularly preferred embodiment, the construct is flanked by sites to facilitate recombinase mediated deletion and homologous recombination of the nucleic acid
5 construct into a target genetic sequence. Alternatively, the construct may be introduced into a host cell where it replicates episomally.

Genetically modified organisms are generated using techniques well known in the art such as described in Hogan *et al.*, *Manipulating the Mouse Embryo: A Laboratory Manual*,
10 Cold Spring Harbour Laboratory Press, CSH NY, 1986; Mansour *et al.*, *Nature* 336:348-352, 1988; Pickert, *Transgenic Animal Technology: A Laboratory Handbook*, Academic Press, San Diego, CA, 1994. Stem cells including embryonic stem cells (ES cells) are introduced into the embryo of a recipient organism at the blastocyst stage of development. There they are capable of integration into the inner cell mass where they develop and
15 contribute to the germ line of the recipient organism. ES cells are conveniently obtained from pre-implantation embryos maintained *in vitro* (Robertson *et al.*, *Nature* 322:445-448, 1986). Once correct targeting has been verified, modified cells are injected into the blastocyst or morula or other suitable developmental stage, to generate a chimeric organism. Alternatively, modified cells are allowed to aggregate with dissociated
20 embryonic cells to form aggregation chimera. The chimeric organism is then implanted into a suitable female foster organism and the embryo allowed to develop to term. Chimeric progeny are bred to obtain offspring in which the genome of each cell contains the nucleotide sequences conferred by the targeting construct. Genetically modified organism may comprise a heterozygous modification or alternatively both alleles may be affected.

25

In accordance with the present invention it is surprisingly determined that Blimp-1 is essential for the production of antibody by ASC but not the commitment to differentiate down the ASC pathway. Accordingly, the identification of Blimp (eg via a reporter molecule co-expressed therewith) in B-cell lineage cells indicates that the cells are
30 committed to differentiate or have differentiated into ASC.

Furthermore, as disclosed herein, Blimp is essential for lymphocyte homeostasis including T-cell homeostasis and the ability of T-cells to become terminally differentiated. The absence of Blimp in adult mammals leads to aggressive multi-organ lymphoproliferative disease.

5

Accordingly, another aspect of the present invention provides a genetically modified cell or non-human organism comprising such cells comprising genetic material encoding a polypeptide which when expressed produces the polypeptide co-expressed with a reporter molecule wherein detection of said reporter molecule is indicative of a cellular phenotype and/or commitment of a cell to terminally differentiate.

10

In a further aspect, the present invention provides a genetically modified cell or non-human organism comprising such cells comprising a modified *Blimp* gene encoding a Blimp polypeptide which when expressed produces Blimp or a part, fragment or functional form thereof co-expressed with a reporter molecule and wherein detection of said reporter molecule is indicative of a cellular phenotype and/or commitment of a cell to terminally differentiate.

15

In a further preferred aspect, the present invention provides a genetically modified cell or non-human organism comprising such cells comprising a modified *Blimp* gene encoding a Blimp mRNA transcript comprising a Blimp coding sequence or a part, fragment or functional form thereof and a reporter molecule encoding sequence, wherein detection of said reporter molecule is indicative of a cellular phenotype and/or commitment of a cell to terminally differentiate

20

25

Preferably, the reporter molecule encoding sequence is inserted with an intron of the *Blimp* allele. In this way, the modified *Blimp* allele co-produces the reporter from a bicistronic RNA under the control of endogenous *Blimp* regulatory elements.

30

Accordingly, another aspect of the present invention provides a genetically modified cell or non-human organism comprising such cells comprising genetic material encoding a

polypeptide which when expressed produces the polypeptide co-expressed with a reporter molecule and wherein detection of said reporter molecule in cells of the haematopoietic system is indicative of a cellular phenotype and/or commitment of a cell to terminally differentiate.

5

In a further aspect, the present invention provides a genetically modified cell or non-human organism comprising such cells comprising a modified *Blimp* gene encoding a Blimp polypeptide which when expressed produces Blimp or a part, fragment or functional form thereof co-expressed with a reporter molecule and wherein detection of said reporter
10 molecule in B-cells is indicative that cells having reporter molecule activity are committed to differentiation into ASC.

In a further preferred aspect, the present invention provides a genetically modified cell or non-human organism comprising such cells comprising a modified *Blimp* gene encoding a
15 Blimp mRNA transcript comprising a Blimp coding sequence or a part, fragment or functional form thereof and a reporter molecule encoding sequence, wherein detection of said reporter molecule in T-cells is indicative that cells having reporter molecule activity are activated T-cells.

20 Preferably, the reporter molecule encoding sequence is inserted with an intron of the *Blimp* allele. In this way, the modified *Blimp* allele co-produces the reporter from a bicistronic RNA under the control of endogenous *Blimp* regulatory elements.

Reference herein to a *Blimp-1* gene or nucleic acid expression product thereof (RNA)
25 includes homologs, parts, fragments, functional forms thereof including functional variants or derivatives which hybridize thereto under low stringency conditions or comprise significant sequence similarity to all or a functional part such as at least about 60% sequence similarity, after optimal alignment. Reference to a Blimp-1 polypeptide or protein is used in a broad sense to include all homologs, parts, fragments or functional
30 forms thereof including functional variants or derivatives bearing at least about 60% amino acid sequence similarity after optimal alignment.

Functional parts of the instant molecules include portions of the full length molecule which are important for the particular functions thereof such as substrate binding, tertiary conformation or transcriptional activity. Transcription initiation sites are readily mapped
5 and sites conferring promoter activity readily identified (see for example Tunyaplin *et al.*, *Nucleic Acid Research* 28(24):4846-4855, 2000). Functional parts are important for regulating the expression and activity of the molecule. Functional variants or derivatives retain at least one of the functional activities important for regulating expression and activity of a reference molecule. With reference to *Blimp-1*, its expression is associated
10 with terminal differentiation, induction of Ig secretion by ASC cells and activation of T-cells.

The modified *Blimp* gene may encode a functionally active Blimp polypeptide, a functionally inactive Blimp polypeptide and/or partial Blimp polypeptide such as a
15 polypeptide or peptide, for example, lacking a zinc finger domain comprising a DNA binding motif. The terms "polypeptide" and "protein" are used interchangeably herein.

A "part" in peptide form may be as small as an epitope comprising less than 5 amino acids or as large as several hundred kilodaltons. The length of the polypeptide sequences
20 compared for homology will generally be at least about 16 amino acids, usually at least about 20 residues, more usually at least about 24 residues, typically at least about 28 residues and preferably more than about 35 residues. A "part" of a nucleic acid molecule is defined as having a minimal size of at least about 10 nucleotides or preferably about 13 nucleotides or more preferably at least about 20 nucleotides and may have a minimal size
25 of at least about 35 nucleotides. This definition includes all sizes in the range of 10-35 nucleotides as well as greater than 35 nucleotides including 50, 100, 300, 500, 600 nucleotides or nucleic acid molecules having any number of nucleotides within these values.

30 The present invention also contemplates modified Blimp alleles encoding variant Blimp polypeptides. "Variant" polypeptides include proteins derived from the native protein by

deletion (so-called truncation) or addition of one or more amino acids to the N-terminal and/or C-terminal end of the native protein; deletion or addition of one or more amino acids at one or more sites in the native protein; or substitution of one or more amino acids at one or more sites in the native protein. Variant proteins encompassed by the present
5 invention are biologically active, that is, they continue to possess the desired biological activity of the native protein (i.e, they are transcriptional repressors of for example c-myc and/or CIITA). Alternatively, the variant Blimp polypeptides are non-functional. Such variants may result from, for example, genetic polymorphism or from human manipulation. Biologically active variants of a native Blimp polypeptide will have at least
10 40%, 50%, 60%, 70%, generally at least 75%, 80%, 85%, preferably about 90% to 95% or more, and more preferably about 98% or more sequence similarity with the amino acid sequence for the native protein as determined by sequence alignment programs described elsewhere herein using default parameters. A biologically active variant of a Blimp polypeptide may differ from that polypeptide generally by as much 100, 50 or 20 amino
15 acid residues or suitably by as few as 1-15 amino acid residues, as few as 1-10, such as 6-10, as few as 5, as few as 4, 3, 2, or even 1 amino acid residue.

A Blimp polypeptide may be altered in various ways including amino acid substitutions, deletions, truncations, and insertions. Methods for such manipulations are generally known
20 in the art. For example, amino acid sequence variants of a Blimp polypeptide can be prepared by mutations in the encoding nucleic acid sequence. Methods for mutagenesis and nucleotide sequence alterations are well known in the art. See, for example, Kunkel (*Proc. Natl. Acad. Sci. USA* 82:488-492, 1985), Kunkel *et al.*, (*Methods in Enzymol.* 154:367-382, 1987), U.S. Pat. No. 4,873,192, Watson *et al.* ("Molecular Biology of the
25 Gene", Fourth Edition, Benjamin/Cummings, Menlo Park, Calif., 1987) and the references cited therein. Guidance as to appropriate amino acid substitutions that do or do not affect biological activity of the protein of interest may be found in the model of Dayhoff *et al.*, (*Natl. Biomed. Res. Found* 5:345-358,1978). For example deletion of all or part of the zinc finger domains containing the DNA binding motif will produce a Blimp variant which is
30 functionally inactive. In some embodiments, animal models are heterozygous in some or all tissues for a genetically modified non-functional Blimp allele, while the other allele

comprises a functional Blimp allele capable of expressing a functional Blimp polypeptide. In other embodiments, homozygous animals are produced which do not express Blimp in particular cells or tissues. Alternatively functional Blimp may be produced by one or two modified Blimp alleles in a cell, tissue or non-human organism. Methods for screening
5 gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property are known in the art. Such methods are adaptable for rapid screening of the gene libraries generated by combinatorial mutagenesis of Blimp polypeptides. Recursive ensemble mutagenesis (REM), a technique which enhances the frequency of functional mutants in the libraries,
10 can be used in combination with the screening assays to identify Blimp polypeptide variants (Arkin *et al.*, *Proc. Natl. Acad. Sci. USA* 89:7811-7815, 1992; Delgrave *et al. Protein Engineering* 6:327-331, 1993). Conservative substitutions, such as exchanging one amino acid with another having similar properties, may be desirable as discussed in more detail below.

15

Variant Blimp polypeptides may contain conservative amino acid substitutions at various locations along their sequence, as compared to the parent Blimp amino acid sequence. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues
20 having similar side chains have been defined in the art, which can be generally sub-classified as follows:

Acidic: The residue has a negative charge due to loss of H ion at physiological pH and the residue is attracted by aqueous solution so as to seek the surface positions in the
25 conformation of a peptide in which it is contained when the peptide is in aqueous medium at physiological pH. Amino acids having an acidic side chain include glutamic acid and aspartic acid.

Basic: The residue has a positive charge due to association with H ion at physiological pH
30 or within one or two pH units thereof (e.g., histidine) and the residue is attracted by aqueous solution so as to seek the surface positions in the conformation of a peptide in

which it is contained when the peptide is in aqueous medium at physiological pH. Amino acids having a basic side chain include arginine, lysine and histidine.

Charged: The residues are charged at physiological pH and, therefore, include amino acids
5 having acidic or basic side chains (i.e., glutamic acid, aspartic acid, arginine, lysine and histidine).

Hydrophobic: The residues are not charged at physiological pH and the residue is repelled
by aqueous solution so as to seek the inner positions in the conformation of a peptide in
10 which it is contained when the peptide is in aqueous medium. Amino acids having a hydrophobic side chain include tyrosine, valine, isoleucine, leucine, methionine, phenylalanine and tryptophan.

Neutral/polar: The residues are not charged at physiological pH, but the residue is not
15 sufficiently repelled by aqueous solutions so that it would seek inner positions in the conformation of a peptide in which it is contained when the peptide is in aqueous medium. Amino acids having a neutral/polar side chain include asparagine, glutamine, cysteine, histidine, serine and threonine.

20 This description also characterises certain amino acids as "small" since their side chains are not sufficiently large, even if polar groups are lacking, to confer hydrophobicity. With the exception of proline, "small" amino acids are those with four carbons or less when at least one polar group is on the side chain and three carbons or less when not. Amino acids having a small side chain include glycine, serine, alanine and threonine. The gene-encoded
25 secondary amino acid proline is a special case due to its known effects on the secondary conformation of peptide chains. The structure of proline differs from all the other naturally-occurring amino acids in that its side chain is bonded to the nitrogen of the α -amino group, as well as the α -carbon. Several amino acid similarity matrices (e.g., PAM120 matrix and PAM250 matrix as disclosed for example by Dayhoff *et al.*, 1978
30 (*supra*); and by Gonnet *et al.*, *Science* 256(5062):1443-1445, 1992), however, include

proline in the same group as glycine, serine, alanine and threonine. Accordingly, for the purposes of the present invention, proline is classified as a "small" amino acid.

5 The degree of attraction or repulsion required for classification as polar or nonpolar is arbitrary and, therefore, amino acids specifically contemplated by the invention have been classified as one or the other. Most amino acids not specifically named can be classified on the basis of known behaviour.

10 Amino acid residues can be further sub-classified as cyclic or noncyclic, and aromatic or nonaromatic, self-explanatory classifications with respect to the side-chain substituent groups of the residues, and as small or large. The residue is considered small if it contains a total of four carbon atoms or less, inclusive of the carboxyl carbon, provided an additional polar substituent is present; three or less if not. Small residues are, of course, always nonaromatic. Dependent on their structural properties, amino acid residues may fall
15 in two or more classes. For the naturally-occurring protein amino acids, sub-classification according to this scheme is presented in the Table A.

Table A
Amino acid sub-classification

Sub-classes	Amino acids
Acidic	Aspartic acid, Glutamic acid
Basic	Noncyclic: Arginine, Lysine; Cyclic: Histidine
Charged	Aspartic acid, Glutamic acid, Arginine, Lysine, Histidine
Small	Glycine, Serine, Alanine, Threonine, Proline
Polar/neutral	Asparagine, Histidine, Glutamine, Cysteine, Serine, Threonine
Polar/large	Asparagine, Glutamine
Hydrophobic	Tyrosine, Valine, Isoleucine, Leucine, Methionine, Phenylalanine, Tryptophan
Aromatic	Tryptophan, Tyrosine, Phenylalanine
Residues that influence chain orientation	Glycine and Proline

Conservative amino acid substitution also includes groupings based on side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulphur-containing side chains is cysteine and methionine. For example, it is reasonable to expect that replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid will not have a major effect on the properties of the resulting variant polypeptide. Whether an amino acid change results in a functional Blimp polypeptide can readily be determined by assaying its activity. Conservative substitutions are shown in Table B below under the heading of exemplary substitutions. More preferred substitutions are shown under the heading of preferred substitutions. Amino acid substitutions falling within the scope of the

invention, are, in general, accomplished by selecting substitutions that do not differ significantly in their effect on maintaining (a) the structure of the peptide backbone in the area of the substitution, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. After the substitutions are introduced, the variants are
5 screened for biological activity.

Table B
Exemplary and Preferred Amino Acid Substitutions

Original Residue	EXEMPLARY SUBSTITUTIONS	PREFERRED SUBSTITUTIONS
Ala	Val, Leu, Ile	Val
Arg	Lys, Gln, Asn	Lys
Asn	Gln, His, Lys, Arg	Gln
Asp	Glu	Glu
Cys	Ser	Ser
Gln	Asn, His, Lys,	Asn
Glu	Asp, Lys	Asp
Gly	Pro	Pro
His	Asn, Gln, Lys, Arg	Arg
Ile	Leu, Val, Met, Ala, Phe, Norleu	Leu
Leu	Norleu, Ile, Val, Met, Ala, Phe	Ile
Lys	Arg, Gln, Asn	Arg
Met	Leu, Ile, Phe	Leu
Phe	Leu, Val, Ile, Ala	Leu
Pro	Gly	Gly
Ser	Thr	Thr
Thr	Ser	Ser
Trp	Tyr	Tyr
Tyr	Trp, Phe, Thr, Ser	Phe
Val	Ile, Leu, Met, Phe, Ala, Norleu	Leu

Alternatively, similar amino acids for making conservative substitutions can be grouped into three categories based on the identity of the side chains. The first group includes glutamic acid, aspartic acid, arginine, lysine, histidine, which all have charged side chains; the second group includes glycine, serine, threonine, cysteine, tyrosine, glutamine, 5 asparagine; and the third group includes leucine, isoleucine, valine, alanine, proline, phenylalanine, tryptophan, methionine, as described in Zubay, G., *Biochemistry*, third edition, Wm.C. Brown Publishers (1993).

Thus, a predicted non-essential amino acid residue in a Blimp polypeptide is typically 10 replaced with another amino acid residue from the same side chain family. Alternatively, mutations can be introduced randomly along all or part of a Blimp polynucleotide coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for an activity of the parent polypeptide to identify mutants which retain that activity. Following mutagenesis of the coding sequences, the encoded peptide can be expressed 15 recombinantly and the activity of the peptide can be determined.

Accordingly, the present invention also contemplates variants of the naturally-occurring Blimp polypeptide sequences or their biologically-active fragments, wherein the variants are distinguished from the naturally-occurring sequence by the addition, deletion, or 20 substitution of one or more amino acid residues. In general, variants will display at least about 30, 40, 50, 55, 60, 65, 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 % similarity to a parent Blimp polypeptide sequence as, for example, set forth in any one of SEQ ID NO: 2 and 4. Desirably, variants will have at least 30, 40, 50, 55, 60, 65, 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence identity to a reference Blimp 25 polypeptide sequence as, for example, set forth in any one of SEQ ID NO: 2 and 4. Moreover, sequences differing from the native or parent sequences by the addition, deletion, or substitution of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more amino acids but which retain the properties of the parent Blimp polypeptide are contemplated. Blimp polypeptides also include polypeptides 30 that are encoded by polynucleotides that hybridise under stringency conditions as defined

herein, especially high stringency conditions, to Blimp polynucleotide sequences, or the non-coding strand thereof.

In some embodiments, variant polypeptides differ from an Blimp sequence by at least one
5 but by less than 50, 40, 30, 20, 15, 10, 8, 6, 5, 4, 3 or 2 amino acid residue(s). In another,
variant polypeptides differ from the corresponding sequence in any one of SEQ ID NO: 2
and 4 by at least 1% but less than 20%, 15%, 10% or 5% of the residues. (If this
comparison requires alignment the sequences should be aligned for maximum similarity.
"Looped" out sequences from deletions or insertions, or mismatches, are considered
10 differences.) The differences are, suitably, differences or changes at a non-essential residue
or a conservative substitution.

A "non-essential" amino acid residue is a residue that can be altered from the wild-type
sequence of an embodiment polypeptide without abolishing or substantially altering one or
15 more of its activities. Suitably, the alteration does not substantially alter one of these
activities, for example, the activity is at least 20%, 40%, 60%, 70% or 80% of wild-type.
An "essential" amino acid residue is a residue that, when altered from the wild-type
sequence of an Blimp polypeptide of the invention, results in abolition of an activity of the
parent molecule such that less than 20% of the wild-type activity is present.

20

In other embodiments, a variant polypeptide includes an amino acid sequence having at
least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%
95%, 96%, 97%, 98% or more similarity to a corresponding sequence of a Blimp
polypeptide as, for example, set forth in any one of SEQ ID NO: 2 and 4.

25

The present invention encompasses Blimp from any mammal or animal (including avian
species) subject such as from humans, non-human primates, livestock, laboratory,
companion or wild animals. Reference to "Blimp" includes Blimp or *Blimp* from any of
the above species as well as structural or evolutionary equivalents or homologs thereof.
30 for example, the present invention encompasses Blimp or a *Blimp* having an amino acid
sequence which has substantially at least about 60% similarity to SEQ ID NO: 2 or 4 or at

least about 60% identity to SEQ ID NO:1, 3, 5 or 6. Reference to at least about 60% includes 60, 61, 62, 63, 64% and all following consecutive numbers in the series to 100%.

Function derivatives of molecules in nucleic acid form include nucleic acid molecules
5 comprising a nucleotide sequence capable of hybridising to the molecule or its complementary form under low stringency conditions.

The terms "similarity" or identity as used herein includes exact identity between compared sequences at the nucleotide or amino acid level. Where there is non-identity at the
10 nucleotide level, "similarity" includes differences between sequences which result in different amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels. Where there is non-identity at the amino acid level, "similarity" includes amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels. In a particularly preferred
15 embodiment, nucleotide and amino acid sequence comparisons are made at the level of identity rather than similarity.

Terms used to describe sequence relationships between two or more polynucleotides or polypeptides include "reference sequence", "comparison window", "sequence similarity",
20 "sequence identity", "percentage of sequence similarity", "percentage of sequence identity", "substantially similar" and "substantial identity". A "reference sequence" is at least 12 but frequently 15 to 18 and often at least 25 or above, such as 30 monomer units, inclusive of nucleotides and amino acid residues, in length. Because two polynucleotides may each comprise (1) a sequence (i.e. only a portion of the complete polynucleotide
25 sequence) that is similar between the two polynucleotides, and (2) a sequence that is divergent between the two polynucleotides, sequence comparisons between two (or more) polynucleotides are typically performed by comparing sequences of the two polynucleotides over a "comparison window" to identify and compare local regions of sequence similarity. A "comparison window" refers to a conceptual segment of typically
30 12 contiguous residues that is compared to a reference sequence. The comparison window may comprise additions or deletions (i.e. gaps) of about 20% or less as compared to the

reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Optimal alignment of sequences for aligning a comparison window may be conducted by computerised implementations of algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics
5 Computer Group, 575 Science Drive Madison, WI, USA) or by inspection and the best alignment (i.e. resulting in the highest percentage homology over the comparison window) generated by any of the various methods selected. Reference also may be made to the BLAST family of programs as, for example, disclosed by Altschul *et al.*, *Nucl. Acids Res.* 25: 3389, 1997. A detailed discussion of sequence analysis can be found in Unit 19.3 of
10 Ausubel *et al.*, *Current Protocols in Molecular Biology* John Wiley & Sons Inc, 1994-1998, Chapter 15).

The terms "sequence similarity" and "sequence identity" as used herein refer to the extent that sequences are identical or functionally or structurally similar on a nucleotide-by-
15 nucleotide basis or an amino acid-by-amino acid basis over a window of comparison. Thus, a "percentage of sequence identity", for example, is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g. A, T, C, G, I) or the identical amino acid residue (e.g. Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp,
20 Glu, Asn, Gln, Cys and Met) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. For the purposes of the present invention, "sequence identity" will be understood to mean the "match percentage" calculated by the DNASIS
25 computer program (Version 2.5 for windows; available from Hitachi Software engineering Co., Ltd., South San Francisco, California, USA) using standard defaults as used in the reference manual accompanying the software. Similar comments apply in relation to sequence similarity.

30 Furthermore, a *Blimp* homolog or derivative may be defined as being capable of hybridising to SEQ ID NO: 1, 3, 5 or 6 or to a complementary form thereof under low

stringency conditions.

Reference herein to a low stringency includes and encompasses from at least about 0 to at least about 15% v/v formamide and from at least about 1 M to at least about 2 M salt for hybridization, and at least about 1 M to at least about 2 M salt for washing conditions. Generally, low stringency is at from about 25-30°C to about 42°C. The temperature may be altered and higher temperatures used to replace formamide and/or to give alternative stringency conditions. Alternative stringency conditions may be applied where necessary, such as medium stringency, which includes and encompasses from at least about 16% v/v to at least about 30% v/v formamide and from at least about 0.5 M to at least about 0.9 M salt for hybridization, and at least about 0.5 M to at least about 0.9 M salt for washing conditions, or high stringency, which includes and encompasses from at least about 31% v/v to at least about 50% v/v formamide and from at least about 0.01 M to at least about 0.15 M salt for hybridization, and at least about 0.01 M to at least about 0.15 M salt for washing conditions. In general, washing is carried out $T_m = 69.3 + 0.41 (G+C)\%$ (Marmur *et al.*, *J. Mol. Biol.* 5: 109, 1962). However, the T_m of a duplex DNA decreases by 1°C with every increase of 1% in the number of mismatch base pairs (Bonner *et al.*, *Eur. J. Biochem.* 46: 83, 1974). Formamide is optional in these hybridization conditions. Accordingly, particularly preferred levels of stringency are defined as follows: low stringency is 6 x SSC buffer, 0.1% w/v SDS at 25-42°C; a moderate stringency is 2 x SSC buffer, 0.1% w/v SDS at a temperature in the range 20°C to 65°C; high stringency is 0.1 x SSC buffer, 0.1% w/v SDS at a temperature of at least 65°C.

Preferably the modified *Blimp* gene is modified using a nucleic acid construct comprising all or a portion of an allele of *Blimp* into which a nucleotide sequence encoding a reporter molecule is inserted.

The reporter molecule is conveniently encoded by a reporter expression cassette or reporter construct. The reporter construct can be brought under the control of the *Blimp-1* regulatory elements and faithfully report the *Blimp-1* expression pattern in cells, tissues or organisms.

By "reporter" is meant any molecule, protein or polypeptide which is typically encoded by a reporter gene and measured in a reporter assay. Reporters provide a detectable signal which permit an understanding of the activity of genetic sequences. They may report an activity directly or may indirectly monitor activity by monitoring the activity of downstream targets. A reporter protein should be distinguishable from other proteins and ideally, readily quantified. The reactivity between an epitope and an antibody determined thereby may readily be employed optionally together with second or further antibodies. Common reporter proteins include luciferase, chloramphenicol transferase (CAT), Beta-galactosidase (B-gal), or fluorescent proteins such as green fluorescent proteins (GFP). Reference herein to GFP is meant to encompass any fluorescent or light-emitting protein including those derived from jelly fish or other organisms and all homologues, derivatives, analogues including colour variants such as DSRed, HcRed, Clontech; or hrGFP, Stratagene). Preferably said reporter expression cassette encodes a fluorescent or other light emitting GFP. GFP reporters are readily detectable in live cells and are particularly useful and preferred in cell sorting applications.

Examples of fluorescent or light emitting markers may be selected from among those included, but are not limited to those, in the following Table 2.

20

TABLE 2

Probe	Ex ¹ (nm)	Em ² (nm)
Reactive and conjugated probes		
Hydroxycoumarin	325	386
Aminocoumarin	350	455
Methoxycoumarin	360	410
Cascade Blue	375; 400	423
Lucifer Yellow	425	528
NBD	466	539
R-Phycoerythrin (PE)	480; 565	578
PE-Cy5 conjugates	480; 565; 650	670
PE-Cy7 conjugates	480; 565; 743	767
APC-Cy7 conjugates	650; 755	767
Red 613	480; 565	613
Fluorescein	495	519
FluorX	494	520

Probe	Ex ¹ (nm)	Em ² (nm)
BODIPY-FL	503	512
TRITC	547	574
X-Rhodamine	570	576
Lissamine Rhodamine B	570	590
PerCP	490	675
Texas Red	589	615
Allophycocyanin (APC)	650	660
TruRed	490, 675	695
Alexa Fluor 350	346	445
Alexa Fluor 430	430	545
Alexa Fluor 488	494	517
Alexa Fluor 532	530	555
Alexa Fluor 546	556	573
Alexa Fluor 555	556	573
Alexa Fluor 568	578	603
Alexa Fluor 594	590	617
Alexa Fluor 633	621	639
Alexa Fluor 647	650	688
Alexa Fluor 660	663	690
Alexa Fluor 680	679	702
Alexa Fluor 700	696	719
Alexa Fluor 750	752	779
Cy2	489	506
Cy3	(512); 550	570; (615)
Cy3,5	581	596; (640)
Cy5	(625); 650	670
Cy5,5	675	694
Cy7	743	767
Nucleic acid probes		
Hoeschst 33342	343	483
DAPI	345	455
Hoechst 33258	345	478
SYTOX Blue	431	480
Chromomycin A3	445	575
Mithramycin	445	575
YOYO-1	491	509
SYTOX Green	504	523
SYTOX Orange	547	570
Ethidium Bromide	493	620
7-AAD	546	647
Acridine Orange	503	530/640
TOTO-1, TO-PRO-1	509	533
Thiazole Orange	510	530
Propidium Iodide (PI)	536	617

Probe	Ex ¹ (nm)	Em ² (nm)
TOTO-3, TO-PRO-3	642	661
LDS 751	543; 590	712; 607
Cell function probes		
Indo-1	361/330	490/405
Fluo-3	506	526
DCFH	505	535
DHR	505	534
SNARF	548/579	587/635
Fluorescent Proteins		
Y66F	360	508
Y66H	360	442
EBFP	380	440
Wild-type	396, 475	50, 503
GFPuv	385	508
ECFP	434	477
Y66W	436	485
S65A	471	504
S65C	479	507
S65L	484	510
S65T	488	511
EGFP	489	508
EYFP	514	527
DsRed	558	583
Other probes		
Monochlorobimane	380	461
Calcein	496	517

¹ Ex: Peak excitation wavelength (nm)

² Em: Peak emission wavelength (nm)

5 Any suitable method of analyzing fluorescence emission is encompassed by the present invention. In this regard, the invention contemplates techniques including but not restricted to 2-photon and 3-photon time resolved fluorescence spectroscopy as, for example, disclosed by Lakowicz *et al.*, *Biophys. J.* 72: 567, 1997, fluorescence lifetime imaging as, for example, disclosed by Eriksson *et al.*, *Biophys. J.* 2: 64, 1993, incorporated herein by reference) and fluorescence resonance energy transfer as, for example, disclosed by Youvan *et al.*, *Biotechnology et Elia* 3: 1-18, 1997).

10

Exemplary fluorophores which may be used in accordance with the present invention

include those discussed by Dower *et al.* (International Patent Publication No. WO 93/06121). Preferably, fluorescent dyes are employed. Any suitable fluorescent dye may be used for incorporation into the instant reporter molecule. For example, reference may be made to U.S. Patent Nos. 5,573,909 (Singer *et al.*) and 5,326,692 (Brinkley *et al.*) which
5 describe a plethora of fluorescent dyes. Reference may also be made to fluorescent dyes described in U.S. Patent Nos. 5,227,487, 5,274,113, 5,405,975, 5,433,986, 5,442,045, 5,451,663, 5,453,517, 5,459,276, 5,515,864, 5,648,270 and 5,723,218.

A modern flow cytometer is able to perform these tasks up to 100,000 cells/particles s⁻¹.
10 Through the use of an optical array of filters and dichroic mirrors, different wavelengths of fluorescent light can be separated and detected simultaneously. In addition, a number of lasers with different excitation wavelengths may be used. Hence, a variety of fluorophores can be used to target and examine, for example, intra- and extra-cellular properties of individual cells. The scattered light measurements can also classify an individual cells's
15 size, shape, granularity and/or complexity and, hence, belonging to a particular population of interest (Shapiro, *Practical flow cytometry*, 3rd Ed., Brisbane, Wiley-Liss, 1995).

Suitable flow cytometers which may be used in the methods of the present invention include those which measure five to nine optical parameters (see Table 3) using a single
20 excitation laser, commonly an argon ion air-cooled laser operating at 15 mW on its 488 nm spectral line. More advanced flow cytometers are capable of using multiple excitation lasers such as a HeNe laser (633 nm) or a HeCd laser (325 nm) in addition to the argon ion laser (488 or 514 nm). Optical parameters, corresponding to different optically detectable/quantifiable attributes, for a carrier, may be measured by a flow cytometer to
25 provide a matrix of qualitative and/or quantitative information, providing a code (or addressability in a multi-dimensional space) for the carrier.

For example, Biggs *et al.* (*Cytometry* 36: 36-45, 1999) have constructed an 11-parameter flow cytometer using three excitation lasers and have demonstrated the use of nine
30 distinguishable fluorophores in addition to forward and side scatter measurements for purposes of immunophenotyping (i.e. classifying) cells. The maximum number of

parameters commercially available currently is 17: forward scatter, side scatter and three excitation lasers each with five fluorescence detectors. Whether all of the parameters can be adequately used depends heavily on the extinction coefficients, quantum yields and amount of spectral overlap between all fluorophores (Malemed *et al.*, "Flow cytometry and sorting", 2nd Ed., New York, Wiley-Liss, 1990). However, it will be understood that the present invention is not restricted to any particular flow cytometer or any particular set of parameters. In this regard, the invention also contemplates use in place of a conventional flow cytometer, a microfabricated flow cytometer as, for example, disclosed by Fu *et al.*, *Nature Biotechnology* 17: 1109-1111, 1999.

10

TABLE 3

Exemplary optical parameters which may be measured by a flow cytometer.

Parameter	Acronym	Detection angle from incident laser beam	Wavelength (nm)
Forward scattered light	FS	2-5°	488
Side scattered light	SS	90°	488
"Green" fluorescence	FL1	90°	510-540
"Yellow" fluorescence	FL2	90°	560-580
"Red" fluorescence	FL3	90°	>650 [#]

15 * using a 488 nm excitation laser

width[†] of bandpass filter

longpass filter

A flow cytometer with this capacity to sort is known as a "fluorescence-activated cell sorter" (FACS). Accordingly, the step of sorting in the present method of obtaining a population of detectably unique carriers may be effected by flow cytometric techniques such as by fluorescence activated cell sorting (FACS) although with respect to the present invention, FACS is more accurately "fluorescence activated carrier or solid support sorting" (see, for example, "Methods in Cell Biology" Vol. 33, Darzynkiewica, Z. and Crissman, H.A., eds., Academic Press).

25

In a further embodiment the present invention provides a method for phenotyping and/or monitoring a cell of the haematopoietic system comprising screening a genetically modified cell or non-human organism comprising such cells comprising a modified *Blimp* gene wherein expression or activity of said gene is indicative of a cellular phenotype and/or a commitment of said cell to terminally differentiate. Haematopoietic cells include but are not limited to B-cells, T-cells, dendritic cells, macrophages and natural killer cells, granulocytes, eosinophils, erythrocytes, megakaryocytes, bone marrow, stromal, splenic precursor cells and their derivatives.

10 Preferably the modified *Blimp* gene encodes a Blimp mRNA transcript comprising a Blimp coding sequence or a part, fragment or functional form thereof and a reporter molecule encoding sequence which when expressed produces Blimp or a part, fragment or functional form thereof co-expressed with a reporter molecule and wherein detection of the reporter molecule is indicative of cellular phenotype and/or commitment of a cell to terminally differentiate.

In a further embodiment, cells which exhibit reporter activity or changes in reporter activity are isolated or selected from among cells which do not exhibit reporter activity. Isolation of reporter-active cells may be by flow cytometry, laser scanning cytometry, chromatography and/or other equivalent procedures. Additionally, further selection markers may be used to isolate or select the modified cells of the present invention. Flow cytometric isolation is particularly preferred.

25 Preferably the cells are ASC identified or isolated in a population of cells of a B-cell lineage.

Accordingly, the present invention provides a method for isolating a substantially purified population of ASC from a population of substantially B-cells said method comprising contacting a genetically modified cell or non-human organism comprising such cells comprising a modified *Blimp* gene with an agent or composition capable of inducing differentiation to ASC wherein expression or activity of said gene is reported by a reporter

construct and wherein detection of said reporter activity is indicative that cells with reporter molecule activity are ASC, where necessary isolating B-cells from said organism and isolating ASC based on the activity of the reporter molecule.

5 Preferably the modified cell comprises a modified *Blimp* gene encoding a Blimp mRNA transcript comprising a Blimp coding sequence or a part, fragment or functional form thereof and a reporter molecule encoding sequence which when expressed produces Blimp or a part, fragment or functional form thereof co-expressed with a reporter molecule and wherein reporter activity is indicative that cells with reporter molecule activity are ASC.

10

Preferably, screening of cells is achieved by flow cytometric analysis of a fluorescent reporter molecule.

B-cells are conveniently isolated from an organism or sample for example by density
15 gradient centrifugation, flow cytometry or using magnetic beads. Any agent or composition which selectively, clonally or polyclonally or otherwise effectively activates B-cells and induces their differentiation to ASC is encompassed. An example of a polyclonal activator is LPS.

20 In one embodiment the reporter is a GFP and said ASC are isolated by flow cytometry.

Substantially purified means that the ASC comprise at least about 60 to 95%, preferably at least about 97%, more preferably at least about 99% of the cells, such as at least about 60,
25 61, 62, 63, 64 and following subsequent numbers in the series to 100%. Alternatively, enrichment of approximately 100,000 fold over unsorted cells is contemplated.

The present invention also provides a method for testing the antigenicity of a vaccine or the ability of agents to enhance or suppress antibody production by ASC wherein reduced
30 reporter activity is indicative of an agent which down regulates or inhibits an antibody response and reporter activity or enhanced reporter activity relative to controls is indicative

of agents which are positive regulators of the antibody response. In accordance with this aspect, the method comprises:

- 5 (i) administering an agent or vaccine to a genetically modified cell or non-human animal comprising such cells wherein the cell or organism comprises a modified *Blimp-1* gene which encodes a Blimp polypeptide which when expressed produces Blimp or a part or fragment or functional form thereof co-expressed with a reporter molecule;
- 10 (ii) testing the cell or organism for the reporter molecule the presence of which is indicative of cellular phenotype and the ability of said agent or vaccine to regulate antibody production by ASC.

In another embodiment, the present invention provides a method for testing the antigenicity or immunogenicity of a vaccine comprising a genetic or proteinaceous
15 composition, the method comprising;

- 20 (i) administering the vaccine to a genetically modified cell or non-human animal comprising such cells wherein the cell or organism comprises a modified *Blimp-1* gene which encodes a Blimp polypeptide which when expressed produces Blimp or a part or fragment or functional form thereof co-expressed with a reporter molecule; and
- (ii) testing the cell or organism for the reporter molecule the presence of which is indicative of the ability of the vaccine to regulate the activation of T-cells and/or B-cells.

25

In some embodiments, the *Blimp* gene encodes a *Blimp* mRNA transcript comprising a Blimp coding sequence or a part, fragment or functional form thereof and a reporter molecule coding sequence. In other embodiments, the reporter molecule coding sequence is inserted within an intron of a *Blimp* allele. In further embodiments, the modified *Blimp*
30 allele is present in homozygous or heterozygous form. Depending upon the purpose of the assay in some embodiments, the modified *Blimp* allele encodes a functional Blimp

transcription factor or a functional part, form, homolog or variant thereof. In other embodiments, the modified *Blimp* allele encodes a non-functional Blimp transcription factor or a non-functional part, form, homolog or variant thereof. In an illustrative embodiment, the cells or genetic material are derived from man, a non-human primate, a
5 livestock, companion or laboratory test organisms, reptilian or amphibian species. Examples of laboratory test animal include a rodent (including mice), guinea pig, pig, duck, rabbit or sheep.

In some illustrative embodiments of the methods disclosed herein the cell is a
10 haematopoietic or embryonic cell. As disclosed herein Blimp is essential for both B-cell and T-cell terminal differentiation and accordingly a preferred cell lineage is a lymphocytic cell. In particular embodiments the lymphocytic cell types is selected from a B-cell and a T-cell. Where a B-cell, the terminally differentiated form is an ASC and these cell can furthermore be substantially purified using the methods disclosed herein. When
15 the cell is a B-cell, the terminally differentiated T-cells include without limitation CD4⁺ T-cells and CD8⁺ T-cells. Conveniently, the detection of the reporter molecule is indicative or predictive of a cellular phenotype and/or commitment of a cell to terminally differentiate under particular conditions or in the presence of test agents. Still more conveniently, the reporter molecule is a fluorescent or light emitting reporter molecule.

20

The present invention also directed to antagonists and agonists of terminal differentiation of cells such as, but not limited to ASC including antagonists and agonists of *Blimp-1* expression or Blimp-1 activity, identified by the herein described method, for use in modulating cellular differentiation. The molecules to which the instant modulators,
25 agonists or antagonists are directed are collectively referred to herein as "targets" or "target molecules".

In another aspect therefore, the present invention provides methods for *in vitro* or *in vivo* screening for agonists or antagonists of terminal differentiation in haematopoietic cells
30 comprising exposing one or more agent/s to a genetically modified cell or non-human animal comprising such cells wherein the cell or organism comprises a modified *Blimp-1*

gene which encodes a Blimp polypeptide which when expressed produces Blimp or a part or fragment or functional form thereof co-expressed with a reporter molecule; and testing the cell or organism for the presence or a change in the level of the reporter molecule the presence of which is indicative of the ability of the one or more agent/s to agonise or
5 antagonise terminal differentiation. Agonists of Blimp directly or indirectly induce terminal differentiation of haematopoietic cells and are useful, for example, in the treatment or prevention of cancer and/or autoimmune disease and in promoting appropriate immune responses to pathological infections. Molecules which inhibit generation of terminally differentiated cells are useful in autoimmune patents such as lupus patients or in
10 treating immune dysfunction such as cases of allergy.

Preferably the modified cell is a haematopoietic cell which comprises a modified *Blimp* gene encoding a Blimp mRNA transcript comprising a Blimp coding sequence or a part, fragment or functional form thereof and a reporter molecule encoding sequence which
15 when expressed produces Blimp or a part, fragment, homolog, variant, derivative or functional or non-functional form thereof co-expressed with a reporter molecule and wherein reporter activity is indicative that cells with reporter molecule activity are terminally differentiated or committed to terminal differentiation. More preferably, the haematopoietic cell is a lymphocyte lineage cell. In some embodiments the terminally
20 differentiated cells are ASC: in other embodiments, the terminally differentiated cells are CD4 T-cell and/or CD8 T-cells. The modified Blimp allele is present in the cell, tissue or non-human organism in homozygous or heterozygous form. Furthermore, depending upon the particular application, the *Blimp* allele expresses a transcriptionally (functionally) active Blimp polypeptide. Thus in some assays it will be useful to have a functional Blimp
25 polypeptide to modulate or induce terminal differentiation in a cell. In other embodiments, the modified Blimp allele does not express a functional Blimp and it will be sufficient to determine, via detection of the reporter activity whether a Blimp allele would have been expressed or whether the level of Blimp expression would have been modulated in a cell capable of producing a function Blimp polypeptide.

30

Cellular (*in vitro*) assays are particularly convenient and, when coupled with a reporter

molecule whose activity can readily be detected in cells, the assays are ideally suited to high throughput screening. A large number of different formats are available as known to the skilled artisan. One useful example is described in Ulleras *et al.*, *Toxicology* 206(2):245-256, 2005.

5

"Modulation" of a molecule or differentiation status includes completely or partially inhibiting or reducing or down regulating all or part of its functional activity or differentiation and enhancing or up regulating all or part its functional activity or differentiation. Where the molecule is a genetic sequence its functional activity may be modulated by, for example, modulating its binding capabilities or transcriptional or translational activity, or its half-life. Where the molecule is an encoded polypeptide, its functional activity may be modulated by, for example, modulating its binding capabilities, its half-life, location in a cell or membrane or its enzymatic capability. Modulators are agonists or antagonists which achieve modulation. Enhanced differentiation can also be indicative of reduced cell division.

An example of an antagonist or agonist is a protein, polypeptide or peptide. These terms may be used interchangeably. These terms refer to a polymer of amino acids and its equivalent and does not refer to a specific length of the product, thus, polypeptides, peptides, oligopeptides and proteins are included within the one definition of a polypeptide. These terms also do not exclude modifications of the polypeptide, for example, glycosylations, acylations, phosphorylations and the like. Included within the definition are, for example, polypeptides containing one or more analogs of an amino acid including, for example, unnatural amino acids such as those given in Table 4 or polypeptides with substituted linkages. Such polypeptides may need to be able to enter the cell. Polypeptides carrying chemical analogs of the amino acids may be more resistant to protease mediated digestion. One example of an antagonist or agonist is a chemical analog of Blimp. Antagonists and agonists may affect the molecules with which Blimp interacts, such as, for example *c-myc* expression is repressed by Blimp-1.

30

Genetic molecules are also developed into agonist and antagonist modulators. The terms "genetic molecule" "nucleic acids", "nucleotide" and "polynucleotide" include RNA, cDNA, genomic DNA, synthetic forms and mixed polymers, both sense and antisense strands, and may be chemically or biochemically modified or may contain non-natural or
5 derivatized nucleotide bases, as will be readily appreciated by those skilled in the art. Such modifications include, for example, labels, methylation, substitution of one or more of the naturally occurring nucleotides with an analog (such as the morpholine ring), internucleotide modifications such as uncharged linkages (e.g. methyl phosphonates, phosphotriesters, phosphoamidates, carbamates, etc.), charged linkages (e.g.
10 phosphorothioates, phosphorodithioates, etc.), pendent moieties (e.g. polypeptides), intercalators (e.g. acridine, psoralen, etc.), chelators, alkylators and modified linkages (e.g. α -anomeric nucleic acids, etc.). Also included are synthetic molecules that mimic polynucleotides in their ability to bind to a designated sequence via hydrogen binding and other chemical interactions. Such molecules are known in the art and include, for example,
15 those in which peptide linkages substitute for phosphate linkages in the backbone of the molecule. Modifications of antisense molecules are well known and are summarised in Kurrek, *Eur. J. Biochem.* 270:1628-1644,2003.

Antisense polynucleotide sequences, for example, are useful in silencing transcripts.
20 Furthermore, polynucleotide vectors containing all or a part of a Blimp gene locus may be placed under the control of a promoter in an antisense orientation and introduced into a cell. Expression of such an antisense construct within a cell will interfere with target transcription and/or translation. Such molecules may be particularly useful in dampening the immune response in autoimmune conditions. Furthermore, co-suppression and
25 mechanisms to induce RNAi or siRNA may also be employed. Alternatively, antisense or sense molecules may be directly administered. In this latter embodiment, the antisense or sense molecules may be formulated in a composition and then administered by any number of means to target cells.

30 A variation on antisense and sense molecules involves the use of morpholinos, which are oligonucleotides composed of morpholine nucleotide derivatives and phosphorodiamidate

linkages (for example, Summerton and Weller, Antisense and Nucleic Acid Drug Development 7: 187-195, 1997). Such compounds are injected into embryos and the effect of interference with mRNA is observed.

5 In one embodiment, the present invention employs compounds such as oligonucleotides and similar species for use in modulating the function or effect of nucleic acid molecules encoding Blimp i.e. the oligonucleotides induce transcriptional or post-transcriptional gene silencing. This is accomplished by providing oligonucleotides which specifically hybridize with one or more nucleic acid molecules encoding the endogenous ligands. The
10 oligonucleotides may be provided directly to a cell or generated within the cell. As used herein, the terms "target nucleic acid" and "nucleic acid molecule encoding an inhibitor" have been used for convenience to encompass DNA encoding the inhibitor, RNA (including pre-mRNA and mRNA or portions thereof) transcribed from such DNA, and also cDNA derived from such RNA. The hybridization of a compound of the subject
15 invention with its target nucleic acid is generally referred to as "antisense". Consequently, the preferred mechanism believed to be included in the practice of some preferred embodiments of the invention is referred to herein as "antisense inhibition." Such antisense inhibition is typically based upon hydrogen bonding-based hybridization of oligonucleotide strands or segments such that at least one strand or segment is cleaved,
20 degraded, or otherwise rendered inoperable. In this regard, it is presently preferred to target specific nucleic acid molecules and their functions for such antisense inhibition.

The functions of DNA to be interfered with can include replication and transcription. Replication and transcription, for example, can be from an endogenous cellular template, a
25 vector, a plasmid construct or otherwise. The functions of RNA to be interfered with can include functions such as translocation of the RNA to a site of protein translation, translocation of the RNA to sites within the cell which are distant from the site of RNA synthesis, translation of protein from the RNA, splicing of the RNA to yield one or more RNA species, and catalytic activity or complex formation involving the RNA which may
30 be engaged in or facilitated by the RNA. In one example, the result of such interference with target nucleic acid function is reduced levels of Blimp. In the context of the present

invention, "modulation" and "modulation of expression" mean either an increase (stimulation) or a decrease (inhibition) in the amount or levels of a nucleic acid molecule encoding the gene, e.g., DNA or RNA. Inhibition is often the preferred form of modulation of expression and mRNA is often a preferred target nucleic acid.

5

An antisense compound is specifically hybridizable when binding of the compound to the target nucleic acid interferes with the normal function of the target nucleic acid to cause a loss of activity, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target nucleic acid sequences under conditions
10 in which specific binding is desired, i.e. under physiological conditions in the case of in vivo assays or therapeutic treatment, and under conditions in which assays are performed in the case of in vitro assays.

"Complementary" as used herein, refers to the capacity for precise pairing between two
15 nucleobases of an oligomeric compound. For example, if a nucleobase at a certain position of an oligonucleotide (an oligomeric compound), is capable of hydrogen bonding with a nucleobase at a certain position of a target nucleic acid, said target nucleic acid being a DNA, RNA, or oligonucleotide molecule, then the position of hydrogen bonding between the oligonucleotide and the target nucleic acid is considered to be a complementary
20 position. The oligonucleotide and the further DNA, RNA, or oligonucleotide molecule are complementary to each other when a sufficient number of complementary positions in each molecule are occupied by nucleobases which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of precise pairing or complementarity over a sufficient number
25 of nucleobases such that stable and specific binding occurs between the oligonucleotide and a target nucleic acid.

According to the present invention, compounds include antisense oligomeric compounds, antisense oligonucleotides, ribozymes, external guide sequence (EGS) oligonucleotides,
30 alternate splicers, primers, probes, and other oligomeric compounds which hybridize to at least a portion of the target nucleic acid. As such, these compounds may be introduced in

the form of single-stranded, double-stranded, circular or hairpin oligomeric compounds and may contain structural elements such as internal or terminal bulges or loops. Once introduced to a system, the compounds of the invention may elicit the action of one or more enzymes or structural proteins to effect modification of the target nucleic acid. One
5 non-limiting example of such an enzyme is RNase H, a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. It is known in the art that single-stranded antisense compounds which are "DNA-like" elicit RNase H. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide-mediated inhibition of gene expression. Similar roles have been
10 postulated for other ribonucleases such as those in the RNase III and ribonuclease L family of enzymes.

While the preferred form of antisense compound is a single-stranded antisense oligonucleotide, in many species the introduction of double-stranded structures, such as
15 double-stranded RNA (dsRNA) molecules, has been shown to induce potent and specific antisense-mediated reduction of the function of a gene or its associated gene products. This phenomenon occurs in both plants and animals.

In the context of the subject invention, the term "oligomeric compound" refers to a
20 polymer or oligomer comprising a plurality of monomeric units. In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics, chimeras, analogs and homologs thereof. This term includes oligonucleotides composed of naturally occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having
25 non-naturally occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for a target nucleic acid and increased stability in the presence of nucleases.

While oligonucleotides are a preferred form of the compounds of this invention, the present invention contemplates other families of compounds as well, including but not limited to oligonucleotides, analogs and mimetics such as those herein described.

5 The open reading frame (ORF) or "coding region" which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is a region which may be effectively targeted. Within the context of the present invention, one region is the intragenic region encompassing the translation initiation or termination codon of the open reading frame (ORF) of a gene.

10

Other target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA (or corresponding nucleotides on the gene), and the 3' untranslated region
15 (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA (or corresponding nucleotides on the gene). The 5' cap site of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an
20 mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap site. It is also preferred to target the 5' cap region.

As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such
25 heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear
30 polymeric compound. In turn, the respective ends of this linear polymeric compound can be further joined to form a circular compound, however, linear compounds are generally

preferred. In addition, linear compounds may have internal nucleobase complementarity and may, therefore, fold in a manner as to produce a fully or partially double-stranded compound. Within oligonucleotides, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or
5 backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those
10 that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

15 Preferred modified oligonucleotide backbones containing a phosphorus atom therein include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and
20 aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein one or more internucleotide linkages is a 3' to 3', 5' to 5' or 2' to 2' linkage. Preferred oligonucleotides having inverted polarity comprise a single 3' to 3' linkage at the 3'-most
25 internucleotide linkage i.e. a single inverted nucleoside residue which may be abasic (the nucleobase is missing or has a hydroxyl group in place thereof). Various salts, mixed salts and free acid forms are also included.

The isolated or recombinant agonists and antagonists of the instant invention are used
30 directly or they may be further modified by methods well known in the art in order to

improve their effectiveness as pharmaceutical or other reagents. Important considerations for an active compound include formulations and methods of delivery.

5 An agonist or antagonist includes molecules determined by all or part of the target in genetic or proteinaceous form, such as antibodies, mimetics or antisense molecules.

Antibodies including anti-idiotypic antibodies, chimeric antibodies and humanised antibodies are useful in this regard and their generation is now routine to those of skill in the art. Peptide or non-peptide mimetics can be developed as agonists of the targets by
10 identifying those residues of the target molecule which are important for function. Modelling can be used to design molecules which interact with the target molecule and which have improved pharmacological properties. All such molecules will need to be modified to permit entry into a cell.

15 Rational drug design permits the production of structural analogs of biologically active polypeptides of interest or of small molecules with which they interact (e.g. agonists, antagonists, inhibitors or enhancers) in order to fashion drugs which are, for example, more active or stable forms of the polypeptide, or which, e.g. enhance or interfere with the function of a polypeptide *in vivo*. See, e.g. Hodgson (*Bio/Technology* 9: 19-21, 1991). In
20 one approach, one first determines the three-dimensional structure of a protein of interest by x-ray crystallography, by computer modeling or most typically, by a combination of approaches. Useful information regarding the structure of a polypeptide may also be gained by modeling based on the structure of homologous proteins. An example of rational drug design is the development of HIV protease inhibitors (Erickson *et al.*, *Science* 249:
25 527-533, 1990). In addition, target molecules may be analyzed by an alanine scan (Wells, *Methods Enzymol.* 202: 2699-2705, 1991). In this technique, an amino acid residue is replaced by Ala and its effect on the peptide's activity is determined. Each of the amino acid residues of the peptide is analyzed in this manner to determine the important regions of the peptide.

It is also possible to isolate a target-specific antibody, selected by a functional assay and then to solve its crystal structure. In principle, this approach yields a pharmacore upon which subsequent drug design can be based. It is possible to bypass protein crystallography altogether by generating anti-idiotypic antibodies (anti-ids) to a functional,
5 pharmacologically active antibody. As a mirror image of a mirror image, the binding site of the anti-ids would be expected to be an analog of the original receptor. The anti-id could then be used to identify and isolate peptides from banks of chemically or biologically produced banks of peptides. Selected peptides would then act as the pharmacore.

- 10 Analogues contemplated herein include but are not limited to modification to side chains, incorporating of unnatural amino acids and/or their derivatives during peptide, polypeptide or protein synthesis and the use of crosslinkers and other methods which impose conformational constraints on the proteinaceous molecule or their analogs.
- 15 Examples of side chain modifications contemplated by the present invention include modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH_4 ; amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS);
20 acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5-phosphate followed by reduction with NaBH_4 .

The guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal
25 and glyoxal.

The carboxyl group may be modified by carbodiimide activation *via* O-acylisourea formation followed by subsequent derivitization, for example, to a corresponding amide.

- 30 Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of a

mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2-chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline
5 pH.

Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides. Tyrosine residues on the other hand, may be altered by nitration with
10 tetranitromethane to form a 3-nitrotyrosine derivative.

Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carbethoxylation with diethylpyrocarbonate.
15

Examples of incorporating unnatural amino acids and derivatives during peptide synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl
20 alanine and/or D-isomers of amino acids. A list of unnatural amino acid, contemplated herein is shown in Table 4.

TABLE 4

Codes for non-conventional amino acids

5	<hr/>			
	Non-conventional amino acid	Code	Non-conventional amino acid	Code
	α -aminobutyric acid	Abu	L-N-methylalanine	Nmala
10	α -amino- α -methylbutyrate	Mgab	L-N-methylarginine	Nmarg
	aminocyclopropane-	Cpro	L-N-methylasparagine	Nmasn
	carboxylate		L-N-methylaspartic acid	Nmasp
	aminoisobutyric acid	Aib	L-N-methylcysteine	Nmcys
	aminonorbornyl-	Norb	L-N-methylglutamine	Nmgln
15	carboxylate		L-N-methylglutamic acid	Nmglu
	cyclohexylalanine	Chexa	L-N-methylhistidine	Nmhis
	cyclopentylalanine	Cpen	L-N-methylisoleucine	Nmile
	D-alanine	Dal	L-N-methylleucine	Nmleu
	D-arginine	Darg	L-N-methyllysine	Nmlys
20	D-aspartic acid	Dasp	L-N-methylmethionine	Nmmet
	D-cysteine	Dcys	L-N-methylnorleucine	Nmnle
	D-glutamine	Dgln	L-N-methylnorvaline	Nmnva
	D-glutamic acid	Dglu	L-N-methylornithine	Nmorn
	D-histidine	Dhis	L-N-methylphenylalanine	Nmphe
25	D-isoleucine	Dile	L-N-methylproline	Nmpro
	D-leucine	Dleu	L-N-methylserine	Nmser
	D-lysine	Dlys	L-N-methylthreonine	Nmthr
	D-methionine	Dmet	L-N-methyltryptophan	Nmtrp
	D-ornithine	Dorn	L-N-methyltyrosine	Nmtyr
30	D-phenylalanine	Dphe	L-N-methylvaline	Nmval
	D-proline	Dpro	L-N-methylethylglycine	Nmetg
	D-serine	Dser	L-N-methyl-t-butylglycine	Nmbug

	D-threonine	Dthr	L-norleucine	Nle
	D-tryptophan	Dtrp	L-norvaline	Nva
	D-tyrosine	Dtyr	α -methyl-aminoisobutyrate	Maib
	D-valine	Dval	α -methyl- γ -aminobutyrate	Mgabu
5	D- α -methylalanine	Dmala	α -methylcyclohexylalanine	Mchexa
	D- α -methylarginine	Dmarg	α -methylcyclopentylalanine	Mcpen
	D- α -methylasparagine	Dmasn	α -methyl- α -naphthylalanine	Manap
	D- α -methylaspartate	Dmasp	α -methylpenicillamine	Mpen
	D- α -methylcysteine	Dmcys	N-(4-aminobutyl)glycine	Nglu
10	D- α -methylglutamine	Dmgln	N-(2-aminoethyl)glycine	Naeg
	D- α -methylhistidine	Dmhis	N-(3-aminopropyl)glycine	Norn
	D- α -methylisoleucine	Dmile	N-amino- α -methylbutyrate	Nmaabu
	D- α -methylleucine	Dmleu	α -naphthylalanine	Anap
	D- α -methyllysine	Dmlys	N-benzylglycine	Nphe
15	D- α -methylmethionine	Dmmet	N-(2-carbamylethyl)glycine	Ngln
	D- α -methylornithine	Dmorn	N-(carbamylmethyl)glycine	Nasn
	D- α -methylphenylalanine	Dmphe	N-(2-carboxyethyl)glycine	Nglu
	D- α -methylproline	Dmpro	N-(carboxymethyl)glycine	Nasp
	D- α -methylserine	Dmser	N-cyclobutylglycine	Ncbut
20	D- α -methylthreonine	Dmthr	N-cycloheptylglycine	Nchep
	D- α -methyltryptophan	Dmtrp	N-cyclohexylglycine	Nchex
	D- α -methyltyrosine	Dmty	N-cyclodecylglycine	Ncdec
	D- α -methylvaline	Dmval	N-cylcododecylglycine	Ncdod
	D-N-methylalanine	Dnmala	N-cyclooctylglycine	Ncoct
25	D-N-methylarginine	Dnmarg	N-cyclopropylglycine	Ncpro
	D-N-methylasparagine	Dnmasn	N-cycloundecylglycine	Ncund
	D-N-methylaspartate	Dnmasp	N-(2,2-diphenylethyl)glycine	Nbhm
	D-N-methylcysteine	Dnmcys	N-(3,3-diphenylpropyl)glycine	Nbhe
	D-N-methylglutamine	Dnmgln	N-(3-guanidinopropyl)glycine	Narg
30	D-N-methylglutamate	Dnmglu	N-(1-hydroxyethyl)glycine	Nthr

	D-N-methylhistidine	Dnmhis	N-(hydroxyethyl)glycine	Nser
	D-N-methylisoleucine	Dnmile	N-(imidazolylethyl)glycine	Nhis
	D-N-methylleucine	Dnmleu	N-(3-indolylyethyl)glycine	Nhtrp
	D-N-methyllysine	Dnmlys	N-methyl- γ -aminobutyrate	Nmgabu
5	N-methylcyclohexylalanine	Nmchexa	D-N-methylmethionine	Dnmmt
	D-N-methylornithine	Dnmorn	N-methylcyclopentylalanine	Nmcpen
	N-methylglycine	Nala	D-N-methylphenylalanine	Dnmphe
	N-methylaminoisobutyrate	Nmaib	D-N-methylproline	Dnmpro
	N-(1-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
10	N-(2-methylpropyl)glycine	Nleu	D-N-methylthreonine	Dnmthr
	D-N-methyltryptophan	Dnmtrp	N-(1-methylethyl)glycine	Nval
	D-N-methyltyrosine	Dnmtyr	N-methyl- α -naphthylalanine	Nmanap
	D-N-methylvaline	Dnmval	N-methylpenicillamine	Nmpen
	γ -aminobutyric acid	Gabu	N-(<i>p</i> -hydroxyphenyl)glycine	Nhtyr
15	L- <i>t</i> -butylglycine	Tbug	N-(thiomethyl)glycine	Ncys
	L-ethylglycine	Etg	penicillamine	Pen
	L-homophenylalanine	Hphe	L- α -methylalanine	Mala
	L- α -methylarginine	Marg	L- α -methylassparagine	Masn
	L- α -methylasspartate	Masp	L- α -methyl- <i>t</i> -butylglycine	Mtbug
20	L- α -methylcysteine	Mcys	L-methylethylglycine	Metg
	L- α -methylglutamine	Mgln	L- α -methylglutamate	Mglu
	L- α -methylhistidine	Mhis	L- α -methylhomophenylalanine	Mhphe
	L- α -methylisoleucine	Mile	N-(2-methylthioethyl)glycine	Nmet
	L- α -methylleucine	Mleu	L- α -methyllysine	Mlys
25	L- α -methylmethionine	Mmet	L- α -methylnorleucine	Mnle
	L- α -methylnorvaline	Mnva	L- α -methylornithine	Morn
	L- α -methylphenylalanine	Mphe	L- α -methylproline	Mpro
	L- α -methylserine	Mser	L- α -methylthreonine	Mthr
	L- α -methyltryptophan	Mtrp	L- α -methyltyrosine	Mtyr
30	L- α -methylvaline	Mval	L-N-methylhomophenylalanine	Nmhph

N-(N-(2,2-diphenylethyl)	Nnbhm	N-(N-(3,3-diphenylpropyl)	Nnbhe
carbamylmethyl)glycine	carbamylmethyl)glycine		
1-carboxy-1-(2,2-diphenyl-	Nmbc		
ethylamino)cyclopropane			

5

Crosslinkers can be used, for example, to stabilize 3D conformations, using homo-bifunctional crosslinkers such as the bifunctional imido esters having (CH₂)_n spacer groups with n=1 to n=6, glutaraldehyde, N-hydroxysuccinimide esters and hetero-bifunctional reagents which usually contain an amino-reactive moiety such as N-hydroxysuccinimide and another group specific-reactive moiety such as maleimido or dithio moiety (SH) or carbodiimide (COOH). In addition, peptides can be conformationally constrained by, for example, incorporation of C_α and N_α-methylamino acids and the introduction of double bonds between C_α and C_β atoms of amino acids.

15

Natural product, combinatorial or phage display technologies are all available for screening for modulators. A huge choice of high through put screening methods are available which may be adapted to employ the cells of the present invention.

20 Two-hybrid screening is also useful in identifying other members of the genetic network acting with of Blimp-1. Target interactions and screens for modulators can be carried out using the yeast two-hybrid system, which takes advantage of transcriptional factors that are composed of two physically separable, functional domains. The most commonly used is the yeast GAL4 transcriptional activator consisting of a DNA binding domain and a transcriptional activation domain. Two different cloning vectors are used to generate separate fusions of the GAL4 domains to genes encoding potential binding proteins. The fusion proteins are co-expressed, targeted to the nucleus and if interactions occur, activation of a reporter gene (e.g. *lacZ*) produces a detectable phenotype. In the present case, for example, *S. cerevisiae* is co-transformed with a library or vector expressing a cDNA GAL4 activation domain fusion and a vector expressing a Myb pathway component fused to GAL4. If *lacZ* is used as the reporter gene, co-expression of the fusion proteins

30

will produce a blue colour. Small molecules or other candidate compounds which interact with a target will result in loss of colour of the cells. Reference may be made to the yeast two-hybrid systems as disclosed by Munder *et al.*, (*Appl. Microbiol. Biotechnol.* 52(3): 311-320, 1999) and Young *et al.*, *Nat. Biotechnol.* 16(10): 946-950, 1998). Molecules thus
5 identified by this system are then re-tested in the genetically modified organisms or genetically modified cells of the present invention.

Pharmaceutical compositions for therapy are further contemplated comprising recombinant, synthetic or isolated forms of the present agonists and antagonists and one or
10 more pharmaceutically acceptable carriers, diluents or excipients. The treatment of cancer or the modulation of an immune response are particularly contemplated.

The term therapy should be taken as a reference to treatment or prophylaxis of a condition or disease. The term "treating" and "ameliorating" are used interchangeably.
15

The terms "composition" or "agent" or "medicament" refer to a chemical compound that induces a desired pharmacological and/or physiological effect. The term also encompass pharmaceutically acceptable and pharmacologically active ingredients of those compounds specifically mentioned herein including but not limited to salts, esters, amides, prodrugs,
20 active metabolites, analogs and the like. When the above term is used, then it is to be understood that this includes the active agent *per se* as well as pharmaceutically acceptable, pharmacologically active salts, esters, amides, prodrugs, metabolites, analogs, etc. The term "compound" is not to be construed narrowly but extends to peptides, polypeptides and proteins as well as genetic molecules such as RNA, DNA and mimetics
25 and chemical analogs thereof.

The phrases "ameliorating a disease or condition" or "treatment" or "therapeutic" are used in the broadest context and include any measurable or statistically significant improvement in a disease or condition or one or more symptoms or frequency of symptoms of a disease
30 or condition as well as complete recovery from the disease or elimination of a condition, its symptoms or its underlying cause. The present invention is applicable to a large range

of diseases or conditions and the skilled addressee must determine the precise parameters of the assessment of phenotypes on a case by case basis. Conditions may be associated with one or more diseases or they may not be so linked. The amelioration of a condition encompasses any desired physiological or psychological change.

5

An effective amount of the instant compositions is established best by those skilled in the art. The term "effective amount" of a compound as used herein means a sufficient amount of the agent to provide the desired therapeutic or physiological effect. Undesirable effects, e.g. side effects, are sometimes manifested along with the desired therapeutic effect; hence,
10 a practitioner balances the potential benefits against the potential risks in determining what is an appropriate "effective amount". The exact amount required will vary from subject to subject, depending on the species, age and general condition of the subject, mode of administration and the like. Thus, it may not be possible to specify an exact "effective amount". However, an appropriate "effective amount" in any individual case may be
15 determined by one of ordinary skill in the art using only routine experimentation.

Pharmaceutical compositions for therapy are further contemplated comprising recombinant, synthetic or isolated forms of the present agonists and antagonists and one or more pharmaceutically acceptable carriers, diluents or excipients. The treatment of cancer
20 or the modulation of an immune response are particularly contemplated.

The term therapy should be taken as a reference to treatment or prophylaxis of a condition or disease. The term "treating" and "ameliorating" are used interchangeably.

25 The terms "composition" or "agent" or "medicament" refer to a chemical compound that induces a desired pharmacological and/or physiological effect. The term also encompasses pharmaceutically acceptable and pharmacologically active ingredients of those compounds specifically mentioned herein including but not limited to salts, esters, amides, prodrugs, active metabolites, analogs and the like. When the above term is used, then it is to be
30 understood that this includes the active agent *per se* as well as pharmaceutically acceptable, pharmacologically active salts, esters, amides, prodrugs, metabolites, analogs,

etc. The term "compound" is not to be construed narrowly but extends to peptides, polypeptides and proteins as well as genetic molecules such as RNA, DNA and mimetics and chemical analogs thereof.

5 The phrases "ameliorating a disease or condition" or "treatment" or "therapeutic" are used in the broadest context and include any measurable or statistically significant improvement in a disease or condition or one or more symptoms or frequency of symptoms of a disease or condition as well as complete recovery from the disease or elimination of a condition, its symptoms or its underlying cause. The present invention is applicable to a large range
10 of diseases or conditions and the skilled addressee must determine the precise parameters of the assessment of phenotypes on a case by case basis. Conditions may be associated with one or more diseases or they may not be so linked. The amelioration of a condition encompasses any desired physiological or psychological change.

15 An effective amount of the instant compositions is established best by those skilled in the art. The term "effective amount" of a compound as used herein mean a sufficient amount of the agent to provide the desired therapeutic or physiological effect. Undesirable effects, e.g. side effects, are sometimes manifested along with the desired therapeutic effect; hence, a practitioner balances the potential benefits against the potential risks in determining what
20 is an appropriate "effective amount". The exact amount required will vary from subject to subject, depending on the species, age and general condition of the subject, mode of administration and the like. Thus, it may not be possible to specify an exact "effective amount". However, an appropriate "effective amount" in any individual case may be determined by one of ordinary skill in the art using only routine experimentation.

25

The polypeptides, nucleic acids, antibodies, peptides, chemical analogs, agonists, antagonists or mimetics of the present invention can be formulated in pharmaceutical compositions which are prepared according to conventional pharmaceutical compounding techniques. See, for example, Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack
30 Publishing, Company, Easton, PA, U.S.A.). The composition may contain the active agent or pharmaceutically acceptable salts of the active agent. These compositions may

comprise, in addition to one of the active substances, a pharmaceutically acceptable excipient, carrier, buffer, stabilizer or other materials well known in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g. intravenous, oral, intrathecal, epineural or parenteral.

For oral administration, the compounds can be formulated into solid or liquid preparations such as capsules, pills, tablets, lozenges, powders, suspensions or emulsions. In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, suspending agents, and the like in the case of oral liquid preparations (such as, for example, suspensions, elixirs and solutions); or carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations (such as, for example, powders, capsules and tablets). Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar-coated or enteric-coated by standard techniques. The active agent can be encapsulated to make it stable to passage through the gastrointestinal tract while at the same time allowing for passage across the blood brain barrier. See for example, International Patent Publication No. WO 96/11698.

For parenteral administration, the compound may be dissolved in a pharmaceutical carrier and administered as either a solution or a suspension. Illustrative of suitable carriers are water, saline, dextrose solutions, fructose solutions, ethanol, or oils of animal, vegetative or synthetic origin. The carrier may also contain other ingredients, for example, preservatives, suspending agents, solubilizing agents, buffers and the like. When the compounds are being administered intrathecally, they may also be dissolved in cerebrospinal fluid.

The active agent is preferably administered in a therapeutically effective amount. The actual amount administered and the rate and time-course of administration will depend on the nature and severity of the condition being treated. Prescription of treatment, e.g.

decisions on dosage, timing, etc. is within the responsibility of general practitioners or specialists and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of techniques and protocols can be found in Remington's
5 Pharmaceutical Sciences, (*supra*).

Alternatively, targeting therapies may be used to deliver the active agent more specifically to certain types of cell, by the use of targeting systems such as antibodies or cell specific ligands. Targeting may be desirable for a variety of reasons, e.g. if the agent is
10 unacceptably toxic or if it would otherwise require too high a dosage or if it would not otherwise be able to enter the target cells.

Instead of administering these agents directly, they could be produced in the target cell, e.g. in a viral vector such as described above or in a cell based delivery system such as
15 described in U.S. Patent No. 5,550,050 and International Patent Publication Nos. WO 92/19195, WO 94/25503, WO 95/01203, WO 95/05452, WO 96/02286, WO 96/02646, WO 96/40871, WO 96/40959 and WO 97/12635. The vector could be targeted to the target cells or expression of expression products could be limited to specific cells, stages of development or cell cycle stages. The cell based delivery system is designed to be
20 implanted in a patient's body at the desired target site and contains a coding sequence for the target agent. Alternatively, the agent could be administered in a precursor form for conversion to the active form by an activating agent produced in, or targeted to, the cells to be treated. See, for example, European Patent Application No. 0 425 731A and International Patent Publication No. WO 90/07936.

25

The present invention is further described by the following non-limiting Examples.

EXAMPLE 1

Generation of a Blimp-1 mutant allele (*Blimp^{gfp}*)

A *Blimp-1* targeting construct was produced in which, inserted into the intron 3' to exon 6,
5 is an *eGFP* expression cassette consisting of a splice acceptor, stop codons in all three
reading frames, an internal ribosome entry site (IRES), the cDNA encoding *eGFP*, and the
SV40 polyadenylation signal to terminate transcription. Also inserted into the intron is a
PGK-Neo^r gene to allow for the selection of embryonic stem (ES) cells with an integrated
targeting vector. The *eGFP* and *Neo^r* cassettes are flanked by *Frt* sites to allow flp
10 recombinase-mediated deletion of the inserted DNA. C57BL/6 ES cells were
electroporated with the *Blimp-1* targeting construct, resistant clones selected by G418
resistance and screened by Southern hybridisation to 5' and 3' genomic DNA probes
(Figure 1C). Four correctly targeted clones carrying the *Blimp^{gfp}* allele (Figure 1C) were
identified from 300 screened colonies. These were injected into BALB/c blastocysts to
15 obtain chimeric founders. These chimeras have been bred, and germ-line transmission has
been achieved with one clone (4F3).

EXAMPLE 2

A GFP reporter that allows the description of the expression pattern of *Blimp-1*

20

Blimp-1 was initially reported to be expressed solely in B-lymphocytes that have been
induced to undergo ASC differentiation (Turner *et al.*, (*supra*)). However, subsequent
studies have revealed a broader expression pattern of Blimp-1 during embryogenesis
(Chang *et al.*, *Mech Dev* 117:305, 2002) and in myeloid cells (Chang *et al.*, (*supra*), 2000).
25 The *Blimp^{gfp}* allele permits a fuller definition of the expression pattern of *Blimp-1*, both
within the haematopoietic lineage and more broadly in the organism. The targeting strategy
outlined above results in a *Blimp^{gfp}* allele that expresses GFP from a bicistronic mRNA
under the control of the endogenous Blimp-1 regulatory elements and is thus predicted to
recapitulate the full *Blimp-1* expression pattern. In addition this strategy interrupts the
30 *Blimp-1* mRNA transcript to produce a truncated version of the Blimp-1 protein (exons 1-
6) that lacks the Zinc finger domains containing the DNA binding motif. In agreement with

this, Western blotting of *Blimp*^{gfp/+} B cells induced to differentiate with LPS *in vitro* demonstrated both the wild type and truncated Blimp-1 protein bands (Figure 1D). By monitoring *GFP* expression in live cells and Blimp-1 protein in fixed tissue, the gene activity and differentiation fate of B-lymphocytes *in vivo* and *in vitro* at the single cell level can be monitored.

EXAMPLE 3

In vivo expression of *Blimp*-1 in ASC

10 Examination of lymphoid tissues in *Blimp*^{gfp/+} mice demonstrated a small population of high Blimp-1 expressing cells in the bone marrow (0.1-0.2%), spleen (0.4-0.6%) and lymph node (0.1%) (Figure 2). Further, phenotypic analysis of the GFP⁺ cells indicated that they represented the previously defined Synd-1 high/B220 low ASC population as well as a previously poorly characterized Synd-1 low to negative phenotype (Figure 2, 15 (Underhill *et al.*, (*supra*))). To confirm that these cells were ASC, GFP⁺ cells from *Blimp*^{gfp/+} bone marrow and spleen were sorted and subjected to ELISpot analysis for Ig production. As can be seen in Figure 3, 75-100% of cells were Ig secreting cells (representative of 3 independent experiments). Moreover sorting of the GFP negative fraction, revealed a frequency of ASC of 0.001% (<1 per 100,000 cells), whereas the 20 frequency of these cells in unsorted bone marrow was between 0.05-0.09% (50-90 per 100,000). Therefore the isolation of *Blimp*^{gfp} expressing ASC gives an enrichment of 100,000 fold over unsorted cells and provides a virtually definitive method to isolate these rare cells. In addition all Ig isotypes were represented in the GFP⁺ ASC populations (Figure 3).

25

To further examine the production of ASC in *Blimp*^{gfp/+} mice using the GFP reporter mice were injected with 2μg lipopolysaccharide (LPS) intravenously and analysed for *GFP* expression 1-7 days post-injection (LPS injection results in the polyclonal activation of mature B cells). LPS injection resulted in a dramatic increase in the numbers of splenic 30 GFP⁺ cells peaking at day 3 post-injection (~5% of total cells) before declining to steady state levels around day 7 (Figure 4A). Analysis of gated GFP⁺ cells indicated that ASC

differentiation occurred in a synchronous wave with the appearance of $\text{Synd-1}^+/\text{B220}^+$ cells followed by $\text{Synd-1}^+/\text{B220}^-$ and finally a fraction of ASC become $\text{Synd-1}^-/\text{B220}^-$. This differentiation is also mirrored in the bone marrow where GFP^+ cells appear at day 4 post-injection as $\text{Synd-1}^+/\text{B220}^+$ cells that rapidly generate the $\text{Synd-1}^{+/-}/\text{B220}^-$ steady state populations (Figure 4B). In summary, LPS treatment induces a wave of ASC
5 differentiation that can be for the first time phenotypically defined using the $\text{Blimp}^{\text{gfp/+}}$ mouse strain.

EXAMPLE 4

10 Expression of *Blimp-1* in ASC derived *in vitro*

A methodology was developed to quantitatively analyse the parameters affecting the commitment to and progression through the ASC lineage *in vitro*. This system involves the isolation of small resting B cells that are purified by Percoll gradient centrifugation and
15 magnetic bead enrichment and cultured in the presence of a variety of stimuli that induce B cell proliferation and differentiation to ASC. These conditions include mimicking a T-dependent response using IL-4 and anti-CD40 or a T-independent reaction using LPS. In addition IL-5 can be titrated into these cultures to accelerate the rate of differentiation and anti-IgD (1.19) crosslinking carried out to activate an antigen specific response. Cultures
20 were assayed on days 1-5 by flow cytometry to measure the frequency of $\text{Blimp}^{\text{gfp}}$ and Synd-1^+ expressing cells. The number of ASC in the culture was determined by ELISPOT.

Analysis of the time course of $\text{Blimp}^{\text{gfp}}$ induction using CD40L/IL-4/IL-5 or LPS (Figure 5A) indicated that the first GFP^+ cells are observed in LPS cultures after 2 days.
25 Thereafter, the numbers of positive cells increases until a peak at day 4 of approximately 50% GFP^+ cells. In contrast CD40L/IL-4/IL-5 treatment results in a delayed induction of fewer GFP^+ expressing cells. Interestingly, whereas the majority of CD40L/IL-4/IL-5 induced GFP^+ expressing cells are also Synd-1^+ , LPS induces both Synd-1^+ and Synd-1^- GFP^+ expressing cells (Figure 5B). To determine if all the GFP^+ cells were actually ASC
30 four fractions from LPS treated $\text{Blimp}^{\text{gfp}}$ B cells were sorted (Figure 5C). ELISPOT assays for IgM, IgG3 and IgG2b clearly show that all the ASC in the cultures are represented by

the GFP⁺ fractions (A, B, C) and is not correlated with the levels of *Synd-1* expression. Moreover, the frequency of ASC did not vary between the GFP⁺ populations (Figure 5C). Thus these data clearly show that whilst *Blimp*^{gfp} is a marker of the ASC fate, *Synd-1*⁺ is only indicative of a sub-population of the ASC activity *in vitro* as it is *in vivo* (Figure 2).

5 The regulation of *Blimp*^{gfp} and *Synd-1* expression was examined using the variety of stimuli outlined above. Interestingly, the frequency of GFP⁺/*Synd-1*⁺ and GFP⁺/*Synd-1*⁻ ASC formation can be modulated by different stimuli as outlined in Figure 5C. Thus, following *Blimp*^{gfp} expression provides a simple and definitive methodology to identify the modulators of ASC induction *in vitro* and *in vivo*.

10 Finally, a transplantation model was developed to demonstrate that *in vitro* derived *Blimp*^{gfp} positive ASC can be detected in the bone marrow or spleen of non-irradiated hosts 7 days after intravenous injection (Figure 6). Therefore, the *Blimp*^{gfp} allele provides a method to examine the effects of *in vitro* treatments of ASC on their survival, migration

15 and functional properties *in vivo*.

EXAMPLE 5

Blimp-1 is required for embryogenesis

20 To produce homozygous *Blimp*^{gfp/gfp} animals *Blimp*^{gfp/+} individuals were intercrossed. Offspring from these crosses were genotyped at day 21 post-birth using *Blimp-1* wild type and *Blimp*^{gfp} specific PCR primers. Whereas *Blimp*^{gfp/+} mice were alive and healthy, no *Blimp*^{gfp/gfp} individuals were identified indicating that *Blimp-1* deficiency results in embryonic or early post-partum lethality (Figure 7). To examine more closely the stage at

25 which *Blimp*^{gfp/gfp} animals die, embryos produced from timed matings of *Blimp*^{gfp/+} mice were examined. These data indicate that *Blimp*^{gfp/gfp} embryos are alive as late as embryonic stage E15.5. However, no viable older individuals have been documented. *Blimp-1* is known to be widely expressed during embryogenesis, a finding that is supported by the analysis using the *Blimp*^{gfp} mouse.

EXAMPLE 6

***Blimp-1* is essential for antibody production**

To circumvent the embryonic lethality of *Blimp*^{gfp/gfp} animals, and examine directly the
5 importance of *Blimp-1* in antibody production fetal liver stem cell reconstitution of lethally
irradiated syngenic mice was used to produce adult mice that lack functional a functional
Blimp-1 protein throughout the haematopoietic system. These *Blimp*^{gfp/gfp} chimeric animals
are healthy and contain relatively normal numbers of all the haematological lineages
examined. *In vitro* analysis of the ASC population in these mice following stimulation with
10 either LPS or CD40L/IL-4 and IL-5 revealed that the presence of GFP⁺ *Blimp* deficient
cells that were predominantly synd-1⁺ (Figure 8A). Importantly, these cells failed to
secrete antibody as assessed by ELISPOT assay (Figure 8B). Therefore, the *Blimp*^{gfp} the
mouse model described here not only provides a definitive tool to isolate ASC but enables
the identification of the population of *Blimp-1* expressing cells from homozygous mutant
15 *Blimp*^{gfp/gfp} splenocytes, thereby greatly facilitating the analysis of the mechanism
underlying the phenotype of *Blimp-1* deficiency.

EXAMPLE 7

Expression of *Blimp-1* in other haematopoietic lineages

20 The *Blimp*^{gfp} reporter system has also enabled for the first time define the expression
pattern of *Blimp-1* in haematopoiesis. As stated above analysis of the lymphoid organs of
Blimp^{gfp} mice revealed that the GFP high producing populations are almost exclusively
ASC. However, lower level GFP producing cells were also apparent.

25 *Blimp-1* has been reported to be expressed by human and mouse macrophages and
granulocytes. Flow cytometric analysis of blood monocytic cells and and bone marrow
derived macrophages cultures in the presence of MCSF-1 revealed clear *Blimp*^{gfp}
expression in these cell types (Figure 9). However, no GFP fluorescence was observed in
30 granulocytes. *In vivo* isolated dendritic cells in contrast lack *Blimp-1* mRNA expression.
Similarly, plasmacytoid and conventional dendritic cells derived from the culture of bone

marrow cells with flt3L lack *Blimp*^{gfp} fluorescence. However, the *ex vivo* activation of sorted dendritic cells or the *in vitro* activation of the flt3L cultures by CpG DNA results in *Blimp*-1 expression predominantly conventional dendritic cells (Figure 10).

- 5 Analysis of thymus and resting spleen from *Blimp*^{gfp/+} mice demonstrated that *Blimp*-1 is not expressed during T cell development. However, a small population of *Blimp*^{gfp} expressing T cells were present in lymph nodes. As these cells could represent the small population of activated T cells present we have stimulated lymph node T cells *in vitro* with an anti-CD3 monoclonal antibody in the presence or absence of concanavalin A,
10 conditions known to strongly activate T cells. In support of the *in vivo* analysis, *in vitro* activated T cells expressed *Blimp*^{gfp} (Figure 12C).

- Examination of the NK lineage in *Blimp*^{gfp} mice revealed that unlike the other haematopoietic lineages examined NK cells constitutively express *Blimp*-1. NK cells were
15 identified from blood, spleen and bone marrow as NK1.1⁺/CD122⁺ cells and demonstrated to be uniformly GFP⁺ (Figure 12A). This expression was maintained *in vitro* as mature NK cells cultured in the presence of IL-15 are GFP⁺ and can be further induced by cytokines such as IL-21 or IL-12/IL-18 that induce NK cell terminal differentiation (Figure 12B). The expression of *Blimp*-1 in NK cells was also confirmed by Western blotting with a
20 *Blimp*-1 specific monoclonal antibody.

- In summary, the *Blimp*^{gfp} reporter mouse has revealed that *Blimp*-1 is induced in the late stages of a variety of haematopoietic lineages thereby providing a method of identifying the regulators of the maturation of these cell types. Importantly, the relatively lower
25 production levels of GFP in non-B lymphoid cell types does not interfere with the isolation of homogenous populations of ASC.

EXAMPLE 8

Examining the role of Blimp-1 in cancer using the *Blimp*^{gfp} mouse

In addition to its utility in examining ASC differentiation, the *Blimp*^{gfp} reporter mouse can
5 be used to examine the malignant transformation of this cell type. Tumors of ASC,
designated plasmacytomas in mice and multiple myeloma in humans, are specifically and
frequently elicited in Eμ-*v-abl* transgenic mice (Rosenbaum *et al.*, (*supra*)), which express
the *v-abl* oncogene in the B cell lineage, under the control of the IgH intronic enhancer.
These mice were crossed with *Blimp*^{gfp} mutant mice, to determine the affect of loss of one
10 or both copies of the *Blimp-1* gene on latency and incidence of tumors. Two outcomes are
envisaged: Blimp-1, by inducing the plasma cell differentiation program, might be required
to open the window of opportunity for *v-abl* transformation. This transgene induces only
plasmacytomas, despite expression in earlier B cells (Rosenbaum *et al.*, (*supra*)).
Therefore, loss of functional *Blimp-1* alleles would be predicted to decrease tumor
15 incidence or increase latency. Alternatively, as a large proportion of *v-abl*-induced
plasmacytomas also bear a rearranged and activated *c-myc* gene, it may be that Myc is an
essential cooperating activity in the transformation (Rosenbaum *et al.*, (*supra*)). Blimp-1 is
believed normally to repress *c-myc* expression during terminal ASC differentiation (Lin *et*
al., *Science* 276:596, 1997). In this scenario, loss of functional Blimp-1 should allow
20 continued *c-myc* expression, which may accelerate plasmacytoma development.

If Blimp-1 is indeed playing a role in ASC tumorigenesis, the *Blimp*^{gfp} reporter strain
provides, therefore, a useful animal model to determe the effects of inhibiting/inducing
Blimp-1 on tumor progression.

EXAMPLE 9

Methods for the Assessment of the role of Blimp in regulating terminal differentiation in T-cells

5 Mice

Blimp^{gfp} (Kallies *et al.*, *J Exp Med* 200:967-977, 2004), *Rag1^{-/-}*, and *Rag2^{-/-}* mice were maintained on a C57BL/6 background. *Blimp^{gfp}* genotyping and foetal liver chimeras were generated as described (Kallies *et al.*, 2004 (*supra*)).

10 Flow cytometry and ELISAs

Monoclonal antibodies (mAbs) against CD4 (GK1.5), CD8 (53.6.7), TCR β (H57-597), Ly5.2 (ALI-4A2) were purified from hybridoma supernatants on Protein G-sepharose columns (Amersham Pharmacia Biotech) and conjugated to biotin (Pierce Chemical Company), allophycocyanin (APC) and phycoerythrin (PE) (ProZyme) as recommended.

15 Biotinylated anti-CD25 (7D4) and CD122 (Tm- β 1) and PE conjugated anti-CD44 (IM7), CD62L (MEL-14) IFN γ $\square\square\square\square$, IL-4 (11B11) were obtained from PharMingen. Biotinylated mAbs were revealed with Streptavidin-PE or Cy5 (Southern Biotechnologies Inc). Cells were analyzed on a LSR cytometer (BD Biosciences) and cell sorting was carried out on high-speed flow cytometers (Moflo cytometry and BD Biosciences).

20 Intracellular staining for cytokines was carried out according to standard procedures known in the art. ELISA for IFN γ and IL-10 production was performed as described (Brady *et al.*, *J Immunol* 172: 2048-2058, 2004). IL-4 ELISA used one monoclonal antibody as a capture reagent and a second monoclonal antibody for detection. ELISAs were performed in triplicate and quantified using recombinant protein standards.

25

Western blotting

Total protein extracts were produced from equivalent numbers of cells and Western blotting was carried out for example as described by Rosenbauer *et al.*, *Embo J* 21:211-20, 2002). Anti-Blimp-1 mAb has been previously described (Kallies *et al.*, 2004 (*supra*)).

30 Equal protein loading was confirmed using anti-Vav1.

HSV infection

Mice were infected with 4×10^5 Herpes Simplex Virus (HSV-1 KOS strain) diluted in 20 μ l PBS. Administration was by subcutaneous injection into the hindleg between the footpad and heel. Spleen and popliteal lymph nodes of infected mice were subsequently
5 harvested for analysis.

***In vitro* cytotoxicity**

gB-specific cytotoxic T-Cell lymphocytes (CTL) were generated by routine procedures.[Belz, 2001]. Spleens were removed from infected mice and single cells were
10 cultured with 10^8 1000 Gy-irradiated gB₄₉₈₋₅₀₅-coated C57BL/6 spleen cells for 5 days. Cytotoxicity was assessed in a conventional ^{51}Cr -release assay. The EL4 (H-2^b) target cells were labelled with Na ^{51}Cr for 1 h and pulsed with gB peptide 60 min, washed twice, and plated at 5,000 targets/well. They were then incubated with the effector populations for 5 h before harvesting supernatants for gamma counting. Two-fold lymphocyte dilutions were
15 assayed in triplicate, while untreated and Triton X-100-disrupted controls were measured in quadruplicate. The percent specific lysis was calculated as $100 \times (\text{51Cr release from targets with effectors} - \text{51Cr release from targets alone}) / (\text{51Cr release from targets with Triton X-100})$. The level of ^{51}Cr release from targets incubated in the absence of T cells was <10% of the total Triton X-100-mediated ^{51}Cr release.

20

Tetramer staining of gB-specific CD8⁺ T cells

Virus-specific CD8⁺ T cells were identified using MHC class I tetrameric complexes [Altman, 1996 #102; Allan, 2003 #100] of the H-2K^b glycoprotein and peptide (SSIEFARL) derived from the glycoprotein B of herpes simplex virus (gB₄₉₈₋₅₀₅).
25 Recombinant H-2K^b molecules with a birA biotinylation motif substituted for the carboxyl-terminal transmembrane domain were refolded with human β_2 -microglobulin plus the viral peptide, biotinylated with birA and complexed at a 4:1 molar ratio with neutravidin-PE (Molecular Probes, Eugene, OR). Lymphocytes were stained for 60 minutes at room temperature with the tetrameric complexes in PBS/BSA/azide, followed
30 by staining with anti-CD8 α APC, washed twice, and analyzed by flow cytometry.

Histology

Organs were fixed in 10% buffered formalin, embedded in paraffin, sectioned and stained with hematoxylin/eosin.

5

EXAMPLE 10

***Blimp* expression can be induced by IL-21, is a key component of the maturation of naïve CD4⁺ and CD8⁺ T-cells into activated effector cells and is essential for normal lymphocyte homeostasis**

- 10 Examination of the lymphoid organs from *Blimp*^{gfp/+} mice revealed a high level GFP in plasma cells. Furthermore, a population of T cells expressed low-levels of GFP (Figure 19A). Further analysis of *Rag1*^{-/-} mice reconstituted with *Blimp*^{gfp/gfp} cells, expressing no functional *Blimp* alleles revealed a pronounced expansion of this same population and a significant increase in GFP fluorescence (Figure 20). More extensive flow cytometric
15 analysis of the T cell compartment of these mice revealed no GFP fluorescence in thymocytes (data not shown) or naïve T cells (Figure 20).

- In contrast and as shown herein, Blimp-1 is expressed specifically in activated/memory type CD4⁺ (TCRβ⁺CD62L^{low}) and CD8⁺ (TCRβ⁺CD44^{high}) T cells (Figure 20). In a more
20 detailed FACS analysis, alternate markers have been used to determine the nature of the expanded T cell pool in Blimp-1 deficient mice. In contrast to mice reconstituted with wildtype fetal liver, *Rag1*^{-/-} mice reconstituted with *Blimp*^{gfp/gfp} cells showed a strong expansion of the CD62L low GFP positive T cell population. Further, these mice had strongly elevated numbers of CD27 low to negative T cells, an increase in CD25 positive
25 CD4 cells as well as a lack of distinct CD122 high population. Analysis using alternate markers, such as CD69, confirmed the activated status of the GFP⁺ cells (data not shown). The increased numbers of effector CD4 T cells in *Blimp*^{gfp/gfp} reconstituted *Rag1*^{-/-} mice was confirmed by *ex vivo* stimulation of isolated splenic CD4 T cells, resulting in 8 to 10 times higher IFN secretion, while secretion of IL-10 was decreased.

30

In vitro culture of naïve T cells in the presence of anti-CD3/CD28 and IL-2 (for CD8⁺ cell) or Th1/Th2 polarizing conditions (for CD4⁺ cells) showed a low level GFP in primary stimulated cultures. However, upon re-stimulation CD4 and CD8 T cells from *Blimp*^{gfp/+} and *Blimp*^{gfp/gfp} mice rapidly became GFP⁺ (Figure 19B). Importantly, Blimp-1 expression
5 in wildtype CD4⁺ effector T cells was confirmed by Western blotting (Figure. 19C). These data demonstrate that the induction of Blimp-1 expression is a component of the maturation of naïve CD4⁺ and CD8⁺ into effector cells.

To further evaluate the Blimp-1 expression after specific antigen stimulation, use was of an
10 infectious disease model. Mice were infected with herpes simplex virus (HSV) and monitored at various time-points post infection for virus specific CD8⁺ T cell primary and memory response using a tetramer specific to the dominant epitope and standard cytotoxic function assays.

15 These experiments confirm the expression of Blimp-1 in antigen specific T cells and indicate that *Blimp*^{gfp/gfp} cells are fully functional in their ability to lyse antigen specific target cells.

The expanded pool of activated T cells observed in the *Blimp*^{gfp/gfp} reconstituted mice
20 suggested aberrant responsiveness or deregulated homeostasis in the absence of Blimp-1. In keeping with this conclusion, *Blimp*^{gfp/gfp} reconstituted mice, displayed pronounced weight loss, ruffled coat and diarrhoea and had to be sacrificed from 6 weeks post-reconstitution. Histological analysis of these mice revealed extensive lymphocyte infiltration and inflammation of a variety of organs including lung, liver and
25 gastrointestinal tract (Figure 21A). The tissue damage was most pronounced in the lung and intestine, implicating this process in the weight loss, diarrhoea and death observed in these mice. Flow cytometric analysis of lymphoid organs and liver of the reconstituted mice revealed a large expansion of fully activated CD4⁺ and CD8⁺ T cells in all organs (Figure 2B). The CD4⁺ cells were primarily Th1 biased. Moreover, reconstitution of
30 *Ragl*^{-/-} mice with *Blimp*^{gfp/gfp} *Rag2*^{-/-} foetal liver did not result in any deaths, strongly implicating T cells in the pathology observed (Figure 21).

To determine if the uncontrolled T cell expansion is intrinsic to the T cells, adoptive transfer experiments were performed of sorted T cells into *Rag1*^{-/-}. In these assays wild-type T cells respond to the lymphopenic environment by undergoing limited homeostatic expansion (Figure 22A). T-cells, 3x10⁶ CD4⁺ or CD8⁺ C57BL/6 or *Blimp*^{gfp/gfp} were
5 injected into *Rag1*^{-/-} recipients and the numbers of splenic T cells assessed 3 weeks post-transfer. As shown in Figure 22A, *Blimp*^{gfp/gfp} T cells of both lineages had a dramatically expanded homeostatic expansion capacity. Moreover, all the resulting T cells expressed GFP and like the wild-type counterparts displayed an activated phenotype (Figure 22). The recipients that received *Blimp*^{gfp/gfp} T cells rapidly developed weight loss, splenomegaly
10 (Figure 22) and a similar range of lymphocyte infiltration phenotypes as described in Figure 21. These data demonstrate that Blimp-1 deficient T cells display a dysregulated expansion that results in multi-organ infiltration and death.

Autoimmunity has been associated with the loss of functional CD4⁺CD25⁺ suppressor T
15 cells. Analysis of this population in *Blimp*^{+gfp} and *Blimp*^{gfp/gfp} CD4⁺ T cells revealed moderate to strong expression of GFP in a fraction of CD25⁺ CD4 T cells suggesting a function for Blimp-1 in the regulatory T cell population. Functional analyses *in vitro* and *in vivo* confirmed unchanged expression of FoxP3, a key factor for Treg, and other genes associated with Tregs. Blimp deficient cells CD4 cells secrete high levels of IFN and
20 show defective IL-10 secretion.

To determine if the dysregulated homeostasis seen in Blimp-1 deficient T cells *in vivo* also manifests itself as enhanced proliferation *in vitro*, cultured naïve CD8⁺ T cells were incubated in the presence of anti-CD3/CD28 and cytokines known to regulate cell
25 proliferation and homeostasis (including IL-2, IL-15 and IL-21). Naïve CD8⁺ cells grown for 7 days in the above conditions showed little GFP expression and similar proliferation profiles between the genotypes (Figure 23A). Similar, results were observed for naïve CD4⁺ cells and those stimulated by PMA/ionomycin combination (data not shown). In contrast, secondary stimulation of the CD8⁺ cells in the presence of IL-2, IL-15 or IL-21
30 resulted in the strong induction of Blimp-1 expression (Figure 23A). In agreement with this expression profile, a significant increase in the cumulative cell number was observed

in the proliferative response of the *Blimp^{gfp/gfp}* cells as compared to Blimp-1 sufficient cells. As expected, a similar strong difference in proliferative potential was observed when activated/memory CD44^{high} cells were used for the primary response. This increase was observed in all cytokine conditions but was most pronounced in the presence of IL-21 (Figure 23B). IL-21 is a T-helper cytokine that was recently shown to be a candidate diabetes susceptibility gene in NOD mice (King, *et al. Cell* 117:265-277, 2004). In that model IL-21 increased effector T cell turnover resulting in lymphopenia induced homeostatic proliferation and diabetes (King, *et al.*, 2004(*supra*)). Interestingly, IL-21 is a potent stimulator of Blimp-1 in B cell terminal differentiation, and was the most efficient inducer of GFP in CD8⁺ T cells suggesting a common role for this cytokine in lymphocyte differentiation.

Molecular and *in vitro* studies have shown that Blimp-1 is a potent transcriptional repressor that can recruit histone methyl-transferases (Gyory *et al.*, *Nat Immunol* 5: 299-308, 2004), deacetylases (Yu *et al.*, *Mol Cell Biol* 20:2592-3603, 2000) and co-repressors of the Groucho family (Ren *et al.*, *Genes Dev* 13:125-137, 1999) to silence targets. Promoter and microarray studies have identified a number of Blimp-1 targets in the B lineage (Shaffer *et al.*, *Immunity* 17:51-62, 2002; Shaffer *et al.*, *Immunity* 21:81-93, 2004). Of these a number including c-myc (Lin *et al.*, *Science* 276:596, 1997), CIITA (Piskurich *et al.*, *Nat Immunol* 1:526-532, 2000), are expressed in the T lineage.

EXAMPLE 11

Blimp is the master regulator of a conserved terminal differentiation program in all lymphocytes.

In summary, the data described herein demonstrate that Blimp-1 is expressed in activated conventional T cells in a variety of contexts. Blimp expression is essential for normal lymphocyte homeostasis as mice injected with Blimp-1 deficient T cells or reconstituted with mutant stem cells die as a result of an aggressive multi-organ lymphoproliferative disease. Additionally, a cytokines such as IL-21 known to regulate the homeostasis of differentiating T cells, was a strong inducer of Blimp-1 expression and supported enhanced

proliferation *in vitro* in the absence of Blimp-1. Accordingly, Blimp-1 expression may be induced in differentiating effector T cells, not by the initial stimulation but towards the completion of the immune response. Blimp-1 is therefore the first transcription factor identified which functions to regulate the genetic program of T cell contraction and/or
5 memory formation that is essential for immune homeostasis.

B and T lymphocytes share many cellular and genetic similarities during their development such as a common progenitor, the ordered VDJ recombination and similar developmental checkpoints, however whilst the terminal differentiation of B cells to plasma cells is a clear
10 functional end-point (Calame *et al.*, *Annu Rev Immunol* 8:8, 2003), the final stages of T cell ontogeny are less defined. The similar functions and expression profile of Blimp-1 within the B and T cell lineages raises the intriguing possibility that despite the outwardly dissimilar appearance, Blimp-1 is the master regulator of a conserved terminal differentiation program in all lymphocytes.

15 Blimp deficiency causes hyperplasia and uncontrolled proliferation while expression of Blimp permits lymphocyte homeostasis and terminal differentiation of haematopoietic cells including ASC, T-cells and B-cells. Accordingly, Cytokines and other immunomodulatory, chemicals, peptides or other small or medium molecular agents which
20 can be screened in the herein described *in vitro* and *in vivo* cellular model systems to determine their potential as therapeutic or prophylactic agents.

Accordingly, the present model reporter systems will be useful in assessing the ability of agents to modulate terminal differentiation in cells of the immune system such as T-cells
25 and B-cells

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also
30 includes all of the steps, features, compositions and compounds referred to or indicated in

this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

BIBLIOGRAPHY

Arkin *et al.*, *Proc. Natl. Acad. Sci. USA* 89:7811-7815, 1992.

Altschul *et al.*, *Nucl. Acids Res.* 25: 3389, 1997.

Angelin-Duclos *et al.*, *J Immunol* 165:5462, 2000.

Angelin-Duclos *et al.*, *Eur J Immunol* 32:3765, 2002.

Ausubel (Ed) *Current Protocols in Molecular Biology*, 5th Edition, John Wiley & Sons, Inc, NY, 2002.

Badovinac *et al.*, *Nat Immunol* 3:619-626, 2002.

Badovinac *et al.*, *Nat Immunol* 5:809-817, 2004.

Bonner and Laskey, *Eur. J. Biochem.* 46: 83, 1974.

Brady *et al.*, *J Immunol* 172: 2048-2058, 2004.

Calame *et al.*, *Annu Rev Immunol* 8:8, 2003.

Chambers *et al.*, *Immunity* 7:885-895, 1997.

Chang *et al.*, *Nat Immunol* 1:169, 2000.

Chang *et al.*, *Mech Dev* 117:305, 2002.

Dayhoff *et al.*, *Natl. Biomed. Res. Found* 5:345-358, 1978.

Delgrave *et al.*, *Protein Engineering* 6:327-331, 1993.

de Souza *et al.*, *Embo J* 18:6062, 1999.

Erickson *et al.*, *Science* 249: 527-533, 1990.

Fong *et al.*, *Proc Natl Acad Sci U S A* 11:11, 2003.

Fontenot *et al.*, *Nat Immunol* 4:330-336, 2003.

Gonnet *et al.*, *Science* 256(5062):1443-1445, 1992.

Gyory *et al.*, *Nat Immunol* 5: 299-308, 2004.

Hodgson, *Bio/Technology* 9: 19-21, 1991.

Hogan *et al.*, *Manipulating the Mouse Embryo: A Laboratory Manual*, Cold Spring Harbour Laboratory Press, CSH NY, 1986.

Hori *et al.*, *Science* 299:1057-1061, 2003.

Kallies *et al.*, *J Exp Med* 200:967-977, 2004.

Keller *et al.*, *Genes Dev* 5:868, 1991.

Khatttri *et al.*, *Nat Immunol* 4:337-342, 2003.

King, *et al.* *Cell* 117:265-277, 2004.

Knodel *et al.*, *Eur J Immunol* 31:1972, 2001.

Kunkel, *Proc. Natl. Acad. Sci. USA* 82:488-492, 1985.

Kunkel *et al.*, *Methods in Enzymol.* 154:367-382, 1987.

Kurreck *et al.*, *Eur. J. Biochem.*, 270:1628-1644, 2003.

Lin *et al.*, *Science* 276:596, 1997.

Mansour *et al.*, *Nature* 336:348-352, 1988.

Manz *et al.*, *Curr Opin Immunol* 14:517, 2002.

Marcu *et al.*, *Annu Rev Biochem* 61:809, 1992.

Marmur *et al.*, *J. Mol. Biol.* 5: 109, 1962.

Medina *et al.*, *Blood* 99:2154, 2002.

Messika *et al.*, *J Exp Med* 188:515, 1998.

Munder *et al.*, *Appl., Microbiol. Biotechnol.* 52(3): 311-320, 1999.

O'Connor *et al.*, *J Exp Med* 195:737, 2002.

Ozaki *et al.*, *J Immunol* 173:5361-5371, 2004.

Pickert, *Transgenic Animal Technology: A Laboratory Handbook*, Academic Press, San Diego, CA, 1994.

Piskurich *et al.*, *Nat Immunol* 1:526-532, 2000.

Remington's Pharmaceutical Sciences, 18th Ed., 1990, Mack Publishing, Company, Easton, PA, U.S.A.

Ren *et al.*, *Genes Dev* 13:125-137, 1999.

Robertson *et al.*, *Nature* 322:445-448, 1986.

Rosenbaum *et al.*, *Embo J* 9:897, 1990.

Rosenbauer *et al.*, *Embo J* 21:211-20, 2002.

Sambrook, *Molecular Cloning: A Laboratory Manual*, 3rd Edition, CSHLP, CSH, NY, 2001.

Schliephake *et al.*, *Eur J Immunol* 26:268, 1996.

Shaffer *et al.*, *Immunity* 17:51-62, 2002.

Shaffer *et al.*, *Immunity* 21:81-93, 2004.

Shapiro, *Practical flow cytometry*, 3rd Ed., Brisbane, Wiley-Liss, 1995.

Shapiro-Shelef *et al.*, *Immunity* 19:607, 2003.

Soro *et al.*, *J Immunol* 163:611, 1999.

Sprent *et al.*, *Annu Rev Immunol* 20:551-579, 2002.

Sprent *et al.*, *Immunol Lett* 85:145-149, 2003.

Summerton and Weller, *Antisense and Nucleic Acid Drug Development* 7: 187-195, 1997.

Tunyaplin *et al.*, *Nucleic Acid Research* 28(24):4846-4855, 2000.

Turner *et al.*, *Cell* 77:207, 1994.

Watson *et al.* "Molecular Biology of the Gene", Fourth Edition, Benjamin/Cummings, Menlo Park, Calif., 1987.

Ulleras *et al.*, *Toxicology* 206(2):245-256, 2005.

Underhill *et al.*, *Blood* 24:24, 2003.

Wells, *Methods Enzymol.* 202: 2699-2705, 1991.

Young *et al.*, *Nat. Biotechnol.* 16(10): 946-950, 1998.

Youvan *et al.*, *Biotechnology et Elia* 3: 1-18, 1997.

Yu *et al.*, *Mol Cell Biol* 20:2592-3603, 2000.